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with a DDA ranging between 70% and 
85% becomes soluble in dilute acidic solu-
tions such as acetic acid or formic acid.[1] 
Indeed, the primary amino groups of chi-
tosan have a pKa of ≈6.5 so that, following 
protonation, they confer upon chitosan 
the feature of solubility in weakly acidic 
aqueous solution, allowing the polymer 
to be easily manipulated.[3] The DDA of 
chitosan plays a key role in determining 
its physicochemical properties, which are 
affected by the proportion of free amino 
groups (–NH2) remaining on the poly-
meric chain upon deacetylation.
Both the primary amino and secondary 
hydroxyl groups behave as reactive func-
tional groups on chitosan. Indeed, these 
groups allow chitosan to be susceptible 
to chemical modifications such as acylation, tosylation, quat-
ernization, alkylation, and O-carboxymethylation.[4] As a result, 
the chitosan structure can be functionalized and optimized to 
improve drug loading or release.[5]
Chitosan-based nanocarriers (ChNCs), including nanopar-
ticles (NPs), micelles, or polyplexes, have received significant 
attention for their numerous advantageous features such as 
natural sourcing, biodegradability, easy functionalizations, and 
low toxicity.[6] The mucoadhesive property of chitosan is key for 
drug delivery purposes.[7] Indeed, chitosan is a positively charged 
polymer that can form electrostatic bonds with the negatively 
charged mucous layer, made of mucin glycoproteins that cover 
the epithelial cells of the mucosa. The establishment of these 
bonds allows drug-loaded ChNCs to exhibit higher absorption 
and retention times at the target, while reducing dosing fre-
quency.[8] Furthermore, chitosan is used as permeation enhancer 
since increases the uptake of the drugs through a transient and 
reversible opening of the tight junctions (TJs) protecting the 
paracellular pathway between endothelial cells in the so-called 
blood–brain barrier (BBB).[9] This is due to F-actin depolymeriza-
tion and leakage of the TJ protein zonula occludens-1.[7]
The small size and large surface area of NCs allow their 
passage through biological membranes, such the BBB, and 
accumulation at the intracellular (such as lysosomes) or intra-
nuclear (DNA or RNA) target site.[10] ChNCs are distinctive for 
their ability to protect the encapsulated therapeutic agent and 
improve its bioavailability by altering the pharmacokinetics.[10]
The endocytic mechanisms responsible for the internaliza-
tion of ChNCs as a drug delivery system may differ according to 
the cell type and the drug to be delivered. Numerous biological 
and pharmacological properties characterize chitosan. These 
include antitumor, antifungal, antioxidant, immunoenhancing, 
and wound healing properties.[11] Furthermore, chitosan is 
Chitosan-based nanocarriers (ChNCs) are considered suitable drug carriers 
due to their ability to encapsulate a variety of drugs and cross biological 
barriers to deliver the cargo to their target site. Fluorescein isothiocyanate-
labeled chitosan-based NCs (FITC@ChNCs) are used extensively in biomed-
ical and pharmacological applications. The main advantage of using FITC@
ChNCs consists of the ability to track their fate both intra and extracellularly. 
This journey is strictly dependent on the physico-chemical properties of the 
carrier and the cell types under investigation. Other applications make use 
of fluorescent ChNCs in cell labeling for the detection of disorders in vivo 
and controlling of living cells in situ. This review describes the use of FITC@
ChNCs in the various applications with a focus on understanding their use-
fulness in labeled drug-delivery systems.
1. Introduction
Chitosan is a polymer derived from the partial alkaline dea-
cetylation of chitin, which represents (after cellulose) the most 
abundant natural polysaccharide, occurring in crustaceans, 
insects, cell walls of fungi, etc.[1] The deacetylation of chitin is a 
treatment performed with 40% sodium hydroxide, at 120 °C for 
up to 3 h.[2] Temperature, duration of the reaction, and concen-
tration of the base determine the degree of deacetylation (DDA) 
and the relative molar mass of the resulting chitosan.[2] Chi-
tosan is composed of poly β-(1→4)-linked 2-acetamido-2-deoxy-
β-D-glucopyranose and 2-amino-2-deoxy-β-D-glucopyranose; 
its structure is shown in Figure  1. The deacetylation of chitin 
is required to overcome the practical disadvantages of chitin 
including high hydrophobicity, insolubility in solvents such 
as water (due to its intramolecular hydrogen bonds), ordinary 
organic solvents, and dilute acid or alkali. In contrast, chitosan 
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biodegradable and biocompatible, and the low costs associ-
ated with its production allow extensive usage in a multitude 
of applications such as pharmaceutics,[12] tissue engineering,[13] 
gene delivery,[14] and drug delivery systems.[15]
Fluorescent NCs offer several advantages and have been 
used extensively in the literature. In fact, such NCs represent 
a valuable tool to quantify the internalization of ChNCs by 
endocytic cells.[16] Moreover, using fluorescently labeled NCs, 
their extracellular and intracellular journey may be efficiently 
tracked in vivo and in vitro.[17] However, the use of fluorescent 
NCs may present challenges. For instance, to avoid nonspecific 
detection, the fluorescent marker must not significantly disso-
ciate from the NC during the uptake experiments or storage. 
This dissociation can occur when the fluorescent marker is 
physically adsorbed on the surface of NCs. Covalent conjuga-
tion of the fluorescent marker to the polymer-based NP can 
help overcoming such issues.[16] Several investigations have 
been performed in the literature employing fluorophores such 
as Cy5.5 or rhodamine which are conjugated to chitosan back-
bone. However, limitations arise since most of the fluorescent 
dyes conjugated to chitosan show photobleaching, toxicity, low 
signal intensity, and poor solubility in water.[18] Instead, fluores-
cein isothiocyanate (FITC) is water soluble, photostable, bio-
compatible, the stable and high intense fluorescence emission 
allows easy detection of small NPs. Its presence does not inter-
fere with ChNCs properties due to the low conjugation density 
and is widely employed in the literature in a variety of fields as 
a tool to study the association of NCs with cells.[18]
Conjugation of FITC with chitosan is performed at room 
temperature by reacting the isothiocyanate group (RNCS) 
present in FITC with the primary amine groups (–NH2) on chi-
tosan, yielding an FITC-labeled Ch (FITC@Ch) based on a thi-
ourea linkage (Figure 1).[2,19] The fluorescently labeled polymer 
is then employed in the formulation of NCs such as NPs, nano-
composites, micelles, or polyplexes.
To help with the visualization of FITC-labeled NCs (FITC@
NCs), some techniques are encompassed in the literature. These 
include the use of confocal laser scanning microscopy (CLSM), 
flow cytometry, fluorescent microscopy, and the trypan blue tech-
niques. The CLSM is a very common imaging technique which 
offers a multiple depth visualization of the sample, obtaining 
a 3D image with a reasonable time resolution. Flow cytom-
etry allows the detection and measurement of the physical and 
chemical features of a population of cells. Fluorescent micros-
copy provides high contrast images of labeled compounds. 
Finally, the trypan blue technique is usually used to quantify live 
cells. It acts by penetrating the cell membrane of dying cells, 
staining them blue. The co-presence of trypan blue and FITC 
induces the quenching of the fluorescent intensity of FITC. As a 
result, if fluorescent NPs were located inside live cells, the green 
fluorescence given by FITC would be preserved.[20]
This review offers a comprehensive appraisal of the bio-
medical and pharmacological applications of FITC@ChNCs 
reported in the literature in the last 20 years.
2. Cellular Uptake Studies and Drug Delivery 
Systems
The cellular uptake of FITC@ChNCs is not compromised by 
the presence of FITC, rather it allows one to perform qualitative 
and quantitative cellular binding studies.[21]
2.1. Cellular Uptake Mechanism Studies
Preliminary studies were undertaken by Huang et  al.[16] who 
investigated the mechanisms of cellular uptake of FITC@
ChNPs by A549 cell monolayers, a human lung cancer cell 
line. The stability of the conjugation of FITC to chitosan was 
Figure 1. Representation of the chemical reaction forming FITC@Ch: 100 mL of dehydrated methanol followed by 50 mL of FITC in methanol (2 mg 
mL−1) was added dropwise to 100 mL of chitosan dissolved in 0.1 m acetic acid (1%) in the dark at room temperature. The reaction was kept for 3 h 
under magnetic stirring so that the amino group on chitosan reacted with the isothiocyanate group on FITC to yield a thiourea linkage on FITC@Ch. 
The labeled polymer was then precipitated in 0.2 m NaOH, pelleted at 40 000 g for 10 min and washed several times with methanol:water (70:30, v/v) 
until no fluorescence was detected in the supernatant (λexc = 490 nm, λemi = 520 nm). FITC@Ch was dissolved in 0.1 m acetic acid and dialyzed in 
5 L water for 3 days in the dark. Finally, the labeled polymer was freeze-dried to obtain a powder. The fluorescence intensity of FITC@Ch solution was 
then measured to determine the labeling efficiency (% w/w FITC to FITC@Ch), against standard solutions of FITC.[21]
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also confirmed at 37  °C in phosphate-buffered saline (PBS) at 
pH 7.4 and culture medium at pH 6.2. Cells were incubated 
with FITC@ChNPs and FITC@Ch (as control) under different 
conditions: at 37 or 4 °C, from 0.5 to 4 h, at pH 6.2, at variable 
concentrations (from 0.2 to 1  mg mL−1). Afterward, cells were 
lysed, and the fluorescence was measured. Quantitative studies 
revealed that the internalization of NPs by A549 cells was con-
centration-, incubation time-, and temperature-dependent: it 
increased with rising doses and incubation times of the NPs. 
Moreover, the uptake of NPs was significantly lower at 4  °C, 
than at 37  °C, suggesting that the uptake could be an energy-
dependent process.[16] Low uptake was observed at 4 °C for both 
the control and FITC@ChNPs, indicating that both the chitosan 
polymer and the ChNPs had the same level of cell bioadhe-
sion. Confocal images confirmed this result; no difference was 
observed at 4  °C while a thicker layer of fluorescent NPs was 
observed at 37 °C compared to the control. To assess the cellular 
uptake pathway undertaken by FITC@ChNPs in A549 cells, 
inhibitors of the uptake pathways were used: hyperosmolarity, 
chlorpromazine, and K+ depletion to inhibit clathrin-mediated 
pathway (CME) and filipin to inhibit the caveolae-mediated 
pathway. Quantitative studies showed that the uptake was 
reduced by 65% only in the presence of hyperosmolarity and K+ 
depletion, while no reduction in the uptake was observed in the 
presence of chlorpromazine and filipin. This result suggested 
that CME was the main pathway undertaken by NPs, albeit the 
internalization of FITC@ChNPs was supported by other path-
ways that did not involve a cellular membrane disruption.[16]
Investigations on A549 cells regarding the uptake of FITC@
ChNPs involved the evaluation of the impact of the molecular 
weight (MW) and DDA of chitosan used to formulate NPs.[22] A 
commercially available chitosan with MW of 213 ± 6 kDa and 
DDA of 88.0 ± 0.5% was used as the starting material and, by 
applying depolymerization with NaNO2, chitosan batches with 
lower MW were produced (98, 48, 17, and 10 kDa). Besides, rea-
cetylation of the commercial chitosan with different amounts 
of acetic anhydride resulted in chitosan with lower DDA (61% 
and 46%). After labeling these with FITC, NPs were formu-
lated by ionic gelation and the resulting NPs showed different 
physicochemical properties in terms of size and zeta potential. 
The surface potential of NPs formulated using all the batches 
of chitosan ranged between +34.6 and +20.3 mV, and chitosan 
with the lowest MW and DDA led to the formation of the 
largest NPs. The low MW chitosan also impacted the labeling 
efficiency of chitosan with FITC, by increasing it from 2.3% to 
8.6%. The same pattern was observed in studies regarding the 
A549 cellular uptake of NPs: NPs formulated using the parent 
chitosan showed higher uptake than those prepared from the 
lowest MW chitosan batches. An analogous trend was observed 
in NPs formulated with the two batches of chitosan having 
lower DDA: the uptakes were 26% and 30% lower than the NPs 
based on the original batch of chitosan. Finally, trypan blue was 
used to distinguish between extracellular and intracellular-asso-
ciated FITC@ChNPs. NPs formulated using the original chi-
tosan induced a higher fluorescence given by FITC, suggesting 
that these NPs were more efficiently taken up by A549 cells 
than those made from the lowest MW and DDA chitosan.[22]
A study performed by Loh et  al.[23] aimed to quantify the 
cellular uptake and hepatotoxicity profile of FITC@ChNPs 
versus FITC@Ch polymer in liver progenitor cells derived 
from healthy human liver tissue.[23] Cellular uptake by endocy-
tosis, limited to particles having a size of 150 nm, was the main 
mechanism by which NPs showed cytotoxicity in the liver. An 
alternative route given by sinusoids is for particles smaller than 
100 nm. In this study, a commercially available chitosan (MW 
202  kDa, DDA 79%) was stained with FITC before forming 
NPs by ionic gelation using a spinning disk processor.[23,24] 
This instrument allowed narrowing of the size distribution 
of NPs even at physiological pH. Indeed, an accurate report 
of particle properties was provided by measuring the size and 
charge at the biological interface level. The authors found that 
FITC@ChNPs had a mean size of ≈20 nm and a surface poten-
tial of −8.4 mV when dispersed in the cell culture medium at 
pH 6. Instead, at pH 7.4, the highest degree of agglomeration 
was recorded. A significantly greater cell–NPs interaction was 
found for FITC@Ch than for FITC@ChNPs, at the same con-
centration, suggesting that chitosan molecules had a higher 
tenacity to bind to cell membrane than the NPs. However, this 
binding was limited to the extracellular membrane, since no 
chitosan was internalized by cells possibly because of its large 
size. This was shown by treatment with trypan blue, recording 
a decrease in fluorescence intensity of FITC.[23] On the other 
hand, NPs were efficiently internalized by the cells, as no dif-
ference in fluorescent intensity was recorded following post-
uptake quenching of trypan blue.[23] However, the mechanisms 
of internalization of NPs have not been elucidated; it has been 
hypothesized that NPs follow the same process as for human 
intestinal cells, namely CME (Figure 2).[23,25]
Recent work aimed to shed light on the understanding of cel-
lular mechanisms behind the interaction of ChNPs with cellular 
membrane, with no therapeutic agent to be delivered.[17] The inter-
action of FITC@ChNPs with two human carcinoma cell lines 
(HeLa—cervical cancer cell line and NCI H460—lung carcinoma 
epithelial cell line) and two human healthy cell lines (BEAS-2B—
lung epithelial cell line and HADF—human dermal fibroblasts) 
was investigated by LigandTracer Green.[17] This instrument can 
detect the real-time association and dissociation profiles of a 
fluorescently labeled ligand with the corresponding receptor on 
the cellular membrane of living cells.[26] From this investigation, 
it was found that ChNPs were successfully internalized by cells 
regardless of the cell line, a behavior explained by the mucoadhe-
sive nature, hydrogen bonding, and hydrophobicity of chitosan.[27] 
Moreover, the use of different inhibitors that block the endocy-
tosis and passive pathways, e.g., nystatin and sodium azide, did 
not inhibit the uptake, albeit this was decreased up to 50% upon 
blockage of the passive pathway. This suggested that more than 
one pathway is involved in the uptake of ChNPs. The CME and 
passive diffusion were the most important pathways involved, 
highlighting the role of the cell membrane in the intracellular 
uptake of ChNPs (Figure 3). Finally, the endocytic pathway role 
was confirmed by lysotracker dye, enabling the visualization of 
NPs entrapped within the lysosomes after 2 h of incubation.[17]
Other investigations were conducted to understand the 
ability of ChNPs to open TJs; monitoring was carried out using 
FITC@ChNPs. Vllasaliu et  al.[28] used Calu-3 cells, a lung 
epithelial carcinoma cell line, to check the passage of ChNPs 
through the epithelial barrier in the context of improving 
mucosal absorption of macromolecules. To study the enhanced 
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permeability effects of NPs, chitosan was compared to ChNPs 
formulated by ionic gelation. After treatment of cells with NPs 
and free chitosan, FITC@ChNPs were detected on the apical 
side of the monolayer, indicating a strong interaction with the 
mucous produced by Calu-3 cells. Moreover, FITC fluorescence 
was detected at the point of contact between cells as demon-
strated in the cell layer images. Following staining of TJs, a 
significant discontinuous loss in fluorescence appeared in 
confocal microscopic images, suggesting structural reorganiza-
tion of cellular TJs following NPs treatment. Finally, this study 
proved that compared to free chitosan, ChNPs significantly 
enhanced the permeability through the cellular monolayer.[28] 
Yeh et al.[29] performed a similar study using FITC@ChNPs to 
investigate the effect of NPs on the opening TJs at the mole-
cular level in the human intestinal Caco-2 cell line. Also, in 
this study, CLSM images showed a strong green fluorescence 
detected at the intercellular spaces of the Caco-2 cell monolayer, 
following treatment with NPs. This suggested the potential for 
ChNPs to open TJs and enhance the paracellular transport of 
epithelial cells (Figure 4).[29]
2.2. Self-Assembled Chitosan-Based NCs
Functional groups on chitosan allow both hydrophilic and hydro-
phobic modifications to occur.[30] Hydrophobically modified 
chitosan provides several advantages including the formation 
of nanosized aggregates and incorporation of hydrophobic 
agents.[30] Polymeric self-assembled NPs have been widely 
employed as drug delivery systems since the hydrophobic core 
allows the incorporation of hydrophobic drugs, while the hydro-
philic shell increases the retention time in the blood, reducing 
any interactions with plasma proteins.[31]
For instance, the use of oleic acid as hydrophobic moiety on 
chitosan, yielding oleoyl-chitosan (O-Ch), can form self-assem-
bled NPs.[30] The cellular uptake of O-Ch NPs was investigated 
in A549 cells, with a focus on particle size, incubation time, 
and concentration.[32] Formulation of NPs occurred by oil/water 
emulsification and FITC was conjugated to these. NPs with 
three different sizes were formulated (198, 247, and 307  nm) 
and used for cellular uptake quantification studies by CLSM. 
After ensuring that the free FITC could not be internalized by 
the cell monolayer, the three sizes of NPs were incubated with 
cells. The uptake was significantly increased with decreasing 
particle diameter, probably due to adsorptive endocytosis. The 
size was found to be a key factor for adhesion and biological 
interaction with the cellular membrane, NPs with a diameter 
between 100 and 200  nm being the most suitable for endocy-
tosis.[33] Moreover, cellular uptake positively correlated with the 
concentration of NPs applied (25 to 400 µg mL−1). However, no 
uptake was observed with the lowest concentration, suggesting 
that a threshold amount is required to begin the cellular uptake. 
Incubation time also played a key role in the cellular uptake as 
it increased up to a saturation point (2 h). Finally, it was noticed 
that a stronger FITC signal was detected around the nucleus 
than in the cytoplasm, indicating that FITC@O-ChNPs also 
surrounded the nucleus.[32]
Broader applications of chitosan as a drug carrier in vivo are 
often limited by its insolubility in physiological solutions (pH 
7.4), leading to precipitation due to interparticle interactions.[34] 
Therefore, chitosan derivatives have been developed to ensure 
solubility in a wide range of pH.[34]
To increase the water solubility of chitosan, much atten-
tion has been paid to depolymerization products of chitosan 
characterized by low MW, yielding chitosan oligosaccharides 
(ChOs).[35] Due to the ability of O-Ch to form self-assembled 
NPs,[30] Zhang et  al.[35] assessed the ability of self-assembled 
oleic acid-modified ChOs (O-ChOs) NPs, generated at physi-
ological pH, to act as anticancer drug NCs. O-ChOs NPs were 
Figure 2. Different behavior showed by FITC@Ch polymer and FITC@
ChNP upon contact with the cell membrane.
Figure 3. Schematic representation of A) clathrin-mediated endocytosis and B) passive endocytosis of FITC@ChNPs.
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conjugated with FITC to perform cellular uptake in vitro 
studies employing A549 cells. After testing FITC@O-ChOs NPs 
on cells at increasing incubation time, fluorescence intensity 
in cell lysate was quantified by fluorimetry. The cellular uptake 
was also investigated by fluorescence microscopy. Quantitative 
results showed that the cellular uptake efficiency increased with 
incubation time and concentration of NPs. This result was sup-
ported by fluorescence microscopy, in which the fluorescence 
signal became stronger with increased incubation time, sug-
gesting that O-ChOs NPs could act as anticancer drug carriers 
by enhancing their cellular uptake of tumor cells.
Chaiyasan et  al.[36] generated self-assembled NPs, as a 
drug delivery system for the ocular surface, by polyelectro-
lyte complexation, employing oppositely charged polymers 
such as cationic chitosan and anionic dextran sulfate (Ds). 
FITC was used to label chitosan and, as drug models, Nile 
Red or Rhodamine B were encapsulated during the genera-
tion of NPs. Adhesion of drug-loaded FITC@Ch/DsNPs to 
the corneal surface, and hence the mucoadhesive properties 
of NPs, was assessed ex vivo in freshly isolated porcine eyes 
and analyzed by fluorescence microscopy.[37] Fluorescence was 
recorded up to 60 min indicating that FITC@Ch/DsNPs were 
retained on the corneal surface for an extended period and 
confirming the NPs’ mucoadhesive properties. The authors[36] 
attributed this property to the high positive surface potential 
of NPs (+40 mV), which interacted with the negatively charged 
mucosal surface.[38,39]
Self-assembled micelles can be prepared from amphiphilic 
derivatives of chitosan such as glycol chitosan.[40] This shows 
improved water solubility in a wide range of pH and biocom-
patibility.[34] Park et  al.[34] generated self-assembled micelles 
formed by the amphiphilic FITC@glycolCh, in which FITC 
represented the hydrophobic core surrounded by glycol chi-
tosan, the hydrophilic shell. The biodistribution of FITC@
glycolCh self-aggregates was explored in tumor-bearing mice, 
by means of the enhanced permeability and retention (EPR) 
effect of tumors.[41] For C57BL/6J mice to develop the tumor, 
skin melanoma B16F10 cells were injected. The solution of self-
aggregates was then administered to tumor-bearing mice; the 
blood and the major organs (tumor, kidney, lung, heart, liver, 
and spleen) were collected. Organs were homogenized, lysed, 
centrifuged, and the supernatant was analyzed by fluorimetry 
to assess the number of fluorescent self-aggregates. Results 
showed that FITC@glycolCh self-aggregates mainly accumu-
lated in the kidney (possibly for secretion) and in the tumor, 
followed by blood, liver, spleen, and lung.[34]
Cho et  al.[40] performed a similar investigation employing 
FITC@glycol ChNPs for biodistribution in tumor-bearing 
mice; B16F10 cells were injected in C57BL/6J mice. FITC@
glycolChNPs were then intravenously (i.v.) administered and, 
after 3 days, blood vessels were stained for nuclei with Hoe-
chst 33342 (a blue dye). The mice were sacrificed 14 days after 
NPs treatment, the tumor was extracted and analyzed on the 
confocal microscope for fluorescence detection. FITC@gly-
colChNPs (green) were mainly identified in the perivascular 
areas (blue), suggesting NPs preferentially extravasate through 
the open fenestrations of the tumor vasculature.[42] This finding 
supported the hypothesis that these polymer-based delivery 
systems are highly selective toward tumors owing to the EPR 
effect.[40]
The intracellular delivery of self-assembled ChNPs was 
investigated by means of FITC on HeLa (human cervical 
cancer cell line), A549, and MDA-MB231 (human breast 
cancer cell line).[43] In this study, the self-assembled NPs were 
prepared by conjugating FITC@glycolCh to N-acetyl histi-
dine, a hydrophobic moiety. The rationale of using N-acetyl 
histidine relied on its ability to become protonated in an 
acidic environment (such as endosomes) inducing disruption 
of the endosomal membrane, NPs dissolution, and release of 
the cargo in the cytosol. The resulting NPs had a mean diam-
eter of 150–250  nm at physiological pH while no NPs were 
detected at lower pH (< 6), due to their dissociation. Flow 
cytometry was used to analyze the cellular uptake: owing 
to nonspecific electrostatic interaction of chitosan with the 
cellular membrane, the uptake was found to be very rapid, 
occurring as early as 10  min. Moreover, confocal studies 
were carried out to evaluate the endocytosis and exocytosis 
dynamics. Results showed that the exocytosis dynamic of NPs 
was dependent on their pre-incubation time with cells: longer 
incubation time allowed more NPs to be endocytosed and less 
NPs to be exocytosed.[43]
2.3. Receptor-Mediated Targeting
The accumulation of drug delivery systems to the target site can 
be achieved by the well-established receptor-mediated targeting 
method.[44] This method refers to drug carriers labeled with a 
ligand direct toward an overexpressed receptor on target cells; 
as a result, the biodistribution of the drug is altered.[44] FITC@
Ch-based NCs have been extensively used to establish the effec-
tiveness of this method, over different tumor cells expressing a 
specific receptor on their surface.
2.4. Epidermal Growth Factor Receptor-2
Owing to the feature of pancreatic cancer cells to overexpress 
epidermal growth factor receptor-2 (HER2),[45] targeted drug 
Figure 4. TJs’ structural reorganization upon treatment with FITC@
ChNPs.
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delivery was achieved by conjugating a monoclonal antibody 
(mAb) toward HER2 to the surface of FITC@ChNPs, so to 
obtain anti-HER2 mAb-modified FITC@ChNPs.[21] Cellular 
binding of anti-HER2 mAb-modified and -unmodified FITC@
NPs was assessed on human pancreatic cancer cell lines (MIA-
Paca 2 and PANC 1). Confocal microscopy and flow cytometry 
images illustrated that the fluorescence, and hence the cellular 
uptake, was higher upon incubation of cells with anti-HER2 
mAb-modified FITC@ChNPs than with unmodified FITC@
ChNPs. Moreover, the fluorescence intensity of an anti-HER2 
mAb-modified FITC@ChNPs increased with incubation time, 
indicating that their internalization was due to receptor-medi-
ated endocytosis.[21,46]
2.5. Glycyrrhetinic Acid Receptors
Rat hepatocytes were shown to possess specific binding sites 
for glycyrrhetinic acid (Ga) on their cellular membranes.[47] 
Ga derives from liquorice and has several biological effects 
including anti-hepatitis and anti-hepatotoxic effects.[48] In this 
regard, Tian et al.[48] formed Ga and polyethylene glycol (PEG)-
modified FITC@ChNPs for targeted drug delivery in the treat-
ment of liver cancer. The cellular uptake of fluorescent NPs, in 
the presence or absence of Ga, was assessed in human hepa-
tocellular carcinoma QGY-7703 cells. Confocal images showed 
that the fluorescence intensity was higher for Ga-modified NPs 
than unmodified, suggesting a stronger cellular association in 
the presence of Ga. The cellular uptake was quantified by flow 
cytometry, showing that more than 70% of cells internalized 
Ga-modified FITC@ChNPs, while only 23% engulfed unmodi-
fied NPs. Overall, these results showed that Ga-grafted in 
ChNPs increased the affinity, hence the cellular uptake toward 
hepatic cells.[48]
Ga was also employed as a hydrophobic group and a ligand 
for liver cells for the generation of micelles based on FITC@
sulfated chitosan (SCh).[49] SCh showed improved water solu-
bility compared to chitosan owing to the presence of sulfate 
groups on the hydroxyl and/or amino groups of chitosan, 
along with good biocompatibility and other biological proper-
ties including blood anticoagulant and antimicrobial activity.[50] 
The suitability of FITC@SCh/Ga micelles as a drug carrier 
system was assessed in terms of biodistribution. Biodistribu-
tion studies were carried out in mice by injecting the solu-
tion of FITC@SCh/Ga micelles into the tail vein. FITC@SCh 
micelles based on stearic acid (Sa) as a hydrophobic group 
were taken as a control. Mice were sacrificed at given time 
points and the blood and major organs (such as liver, kid-
neys, heart, spleen, and lung) were isolated. The organs were 
homogenized, lysed, and centrifuged, and the supernatant was 
analyzed by a fluorimeter. The fluorescence intensity in the 
plasma was also measured. It was found that the livers of mice 
treated with FITC@SCh/Ga micelles showed a higher uptake 
than the other tissues, whereas the highest concentration of 
FITC@SCh/Sa micelles (control) was seen in the blood and 
not in the liver. This was confirmed by fluorescence micros-
copy. Moreover, results followed a similar trend regarding time 
after injection; FITC@SCh/Ga micelles accumulated in the 
liver as early as 15 min and up to 24 h after injection, whereas 
a low accumulation in the liver of FITC@SCh/Sa was recorded 
at all time points. Overall, these results indicated a high tar-
geting ability of the investigated micelles due to the presence 
of Ga.[49]
Cheng et  al.[51] employed Ga-modified FITC@ChNPs to 
assess their cellular uptake by human hepatoma SMMC-7721 
cells against healthy liver LO2 cells. In this study, Ga-modified 
FITC@ChNPs served as a carrier system of 5-fluorouracil, an 
anti-cancer drug with limited clinical use due to unwanted 
side-effects.[52] Following incubation of cells with Ga-modified 
FITC@ChNPs, CLSM images displayed a stronger green signal 
in SMMC-7721 cells than LO-2 cells, indicating a preferential 
uptake of these NPs by cancer cells, engulfing them through a 
receptor-mediated transport system.[51]
2.6. Asialoglycoprotein Receptors
Asialoglycoprotein receptors (AGP-R) are highly expressed on 
the surface of hepatocytes and widely used in targeted drug 
delivery to the liver.[53] The AGP-R is a transmembrane C-type 
lectin that recognizes a wide range of ligands with terminal 
galactose (Gal) or N-acetylgalactosamine (GalNAc) residues.[54] 
To generate NPs that specifically bind to AGP-R, Zhu et  al.[55] 
employed lactobionic acid (La), a disaccharide formed by glu-
conic acid and galactose, conjugated to ChOs, a water-soluble 
derivative of chitosan.[35] Adenosine triphosphate (ATP), highly 
involved in the transport of chemical energy in the liver,[56] was 
used as a hydrophobic and negatively charged cargo for the 
generation of NPs. In vitro cellular uptake of ChOs/La NPs was 
investigated in HepG2 cells by means of FIT@NPs. La-unmod-
ified FITC@ChOsNPs were used as a control. CLSM images 
showed that the fluorescence intensity of FITC@ChOs/La NPs 
was much stronger than that of the control, suggesting that La-
modified NPs were engulfed by hepatic cells owing to binding 
with the AGP-R.[55]
2.7. Sigma Receptors
Garg et  al.[57] aimed to deliver the anticancer drug, Gemcit-
abine, to A549 cells employing ChNPs modified with PEG 
and anisamide, which is a ligand of sigma receptors, highly 
expressed on several tumors including lung cancer cells.[58] To 
perform cellular binding studies, the probe FITC was added 
on NPs structure in place of the drug and the resulting flu-
orescent NPs were incubated with A549 cells. The cellular 
uptake was higher for cells incubated with anisamide-mod-
ified FITC@Ch/PEGNPs than for unmodified NPs and free 
FITC, suggesting that the cellular uptake mainly occurred by a 
receptor-mediated endocytosis.[46] Inhibition studies were also 
performed by treating cells with haloperidol (a high-affinity 
ligand for the sigma receptor), before adding the fluorescent 
NPs. Haloperidol treatment significantly decreased the cel-
lular uptake of anisamide-modified FITC@Ch/PEGNPs, 
yielding the same results as for unmodified FITC@Ch/
PEGNPs. These results suggested that functionalizations of 
NPs with anisamide was key for the uptake of NPs by lung 
cancer cells.[57]
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2.8. Transferrin Receptor
The transferring receptor (Tf-R) is located on the cerebral 
endothelial cells that constitute the BBB and are responsible 
for iron intake.[59] The BBB prevents any harmful substances 
from reaching the brain and allows passage only to selected 
molecules or nutrients by passive or active transport.[60] Active 
transport includes adsorptive-mediated, receptor-mediated, 
carrier-mediated, and cell-mediated transcytosis.[61] Because 
of the BBB’s selectivity, many therapeutics cannot reach 
the brain to treat diseases. However, it has been found that 
by modifying the surface of NPs with an mAb toward Tf-R, 
such as OX-26 mAb, NPs can reach the brain and deliver their 
cargo.[62] Monsalve et  al.[63] employed FITC@CsNPs func-
tionalized with OX-26 mAb and PEG to improve their pas-
sage through the BBB. In vivo experiments were performed 
on BALB/c mice through intraperitoneal injection of OX-26 
mAb-modified and unmodified FITC@CsNPs (control). The 
mice were then sacrificed and each section of the brain (hip-
pocampus, cortex, striatum, corpus callosum, and thalamus) 
was analyzed using CLSM. Images illustrated a stronger 
fluorescence in the hippocampus of mice treated with OX-26 
mAb-modified FITC@CsNPs compared to other regions of 
the brain and to the control. This showed that OX-26 mAb-
modified FITC@CsNPs were able to cross the BBB in vivo at 
a higher extent than unmodified FITC@CsNPs and that the 
triggered mechanism was receptor-mediated endocytosis. Fur-
ther, staining of the hippocampus nuclei demonstrated that 
the labeled NPs were in the perinuclear region, confirming 
their ability to be engulfed by the cells. Finally, the brain 
microvessels were analyzed by CLSM and stronger adhesion 
of OX-26 mAb-modified FITC@CsNPs than the control was 
found on the microvessel surfaces, due to the interaction with 
Tf-R.[63]
2.9. Mucin 1 Receptor
Mucin 1 receptor (MUC1) is a glycoprotein overexpressed in 
epithelial cancers and used as tumor marker.[64] A study con-
ducted by Varnamkhasti et al.[65] showed the targeting efficiency 
of FITC@ChNPs against colon cancer cells. The positive charge 
of chitosan was used as core for the negatively charged hyalu-
ronic acid (highly expressed in colon cancer)[66] conjugated with 
SN-38 (the active form of irinotecan), a well-known chemother-
apeutical drug to treat colon cancer. Finally, NPs were modified 
with a DNA aptamer designed against MUC1. In vitro uptake 
studies were conducted against HT-29, a human colon cancer 
adenocarcinoma cell line and a Chinese hamster ovarian cell 
line (CHO). The uptake detection of NPs, in which the chitosan 
core was labeled with FITC, was performed by flow cytometry. 
Results showed a different ability to internalize NPs by the two 
different cell lines: HT-29 cell line showed higher uptake than 
the CHO. Moreover, analysis of the mean fluorescence inten-
sity showed that the uptake for aptamer-modified NPs was 
twice that of unmodified NPs. These results confirmed that the 
aptamer modification was efficient in increasing the uptake of 
NPs by colon cancer cells, owing to the external expression of 
MUC1.[65]
2.10. Folic Acid Receptor
Folic acid receptor (FA-R) is overexpressed on the membrane of 
numerous epithelial tumor cells and FA can be used as a tar-
geting agent.[67] Keresztessy et al.[68] explored the possibility for 
self-assembled NPs composed of FITC@Ch and FA-conjugated 
poly-γ-glutamic acid (γPGA) to act as a drug delivery system 
in cancer. NP’s cellular uptake was explored in ovarian cancer 
A2780/AD cells, known to overexpress the FA-R.[69] Confocal 
images showed that FITC@Ch/FA-γPGANPs were successfully 
engulfed by cells after 1 h incubation and were found mainly in 
the cytoplasm of cells. In contrast, FA-unmodified NPs showed 
a very poor cellular uptake since only weak fluorescence was 
recorded. This result was confirmed by quantification studies 
performed by processing the intensity of the pixels of the digital 
photographs. Z-sections performed using CLSM showed that 
FITC@Ch/FA-γPGANPs were distributed in the cytoplasm in 
different layers, excluding the possibility for them only to adhere 
to the cell surfaces. This study concluded that conjugation of FA 
to NPs can effectively enhance their cellular uptake.[68]
To test the effectiveness of a tumor-targeted drug delivery 
system, Hua et  al.[70] grafted FA into FITC@ChNPs, coated 
with the hydrophilic poly(sulfobetaine methacrylate) and loaded 
with etoposide (VP-16), a poorly water-soluble chemotherapeutic 
drug. The cellular uptake of NPs was assessed in the human 
cervical carcinoma, HeLa cells, overexpressing the FA-R.[71] Con-
focal images showed enhanced antitumor activity of FA-grafted 
NPs. Further in vivo investigations were pursued by injecting 
HeLa cells into male C57BL/6 mice and female athymic nude 
mice, to establish tumor xenograft models (Figure  5). Drug-
loaded NPs were administered intravenously, and the drug’s 
pharmacokinetics was assessed through measurements of the 
blood retention time, indicating a half-life of about 10 h, which 
is much longer than the half-life of free VP-16 (less than 1 h). 
When looking at the tumor site in the mice, it was noted that 
those treated with FA-coated FITC@ChNPs showed stronger 
fluorescent signaling after 2 h treatment while in mice treated 
with uncoated NPs, the signal was detected after 24 h. This 
proved the greater targeting effect of FA-coated NPs. Finally, 
after 48 h of NPs treatment, the mice were sacrificed and a small 
fluorescent signal (due to FITC) was detected in both liver and 
spleen, indicating an accumulation of NPs in these organs for 
their clearance by the mononuclear phagocytic system (MPS).
To improve the targeted drug delivery, researchers attempted 
to increase the ligand density of NPs.[72] However, this strategy 
may result in several disadvantages such as increased immu-
nogenicity and reduced water solubility.[73,74] To overcome these 
limitations, Cao et  al.[75] generated a multivalent drug delivery 
system based on chitosan modified with succinic acid (Sa) (con-
ferring high stability in the blood owing to its negative surface 
charge)[76] and poly(acrylic acid) (Paa), which provides a scaf-
fold for multivalent (mv) folate ligands (Paa-mvFA). Indeed, 
Paa was shown to increase the water solubility of hydrophobic 
ligands and the flexible configuration allowed multivalent 
ligands to match the conformational demands of receptors.[77] 
Cellular uptake studies of the resulting NPs were performed 
on HepG2 cells (FA-R negative) and the human oral epithe-
lioid cancer KB cells (FA-R positive), by labeling chitosan with 
FITC, before generating NPs. CLSM images showed that 
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FITC@Ch/Sa/Paa-mvFA were successfully engulfed by KB cells 
owing to their expression of the FA-R. FITC@Ch/Sa were used 
as control and their cellular uptake was negligible, indicating no 
interference with the targeting ability of mvFA NPs. Moreover, 
no uptake was occurring in the absence of FA, meaning that the 
internalization occurred through receptor-mediated transport. 
Quantitative studies performed by flow cytometry showed that, 
when KB cells were incubated with FITC@Ch/Sa/Paa-mvFA, 
the mean fluorescence was significantly higher than monovalent 
NPs. This result indicated that the high ligand valency induced 
an enhanced targeting ability. Investigation on HepG2 cells 
(FA-R negative) indicated that a very low cellular uptake occurred 
upon treatment with FITC@Ch/Sa/Paa-mvFA. Finally, a com-
petitive assay in the presence of an excess of folate on KB cells 
(FA-R positive) showed that the uptake of FITC@Ch/Sa/Paa-
mvFA by FA-R was negligible. Collectively, these results showed 
that the receptor-mediated endocytosis played the key role in the 
internalization process of FITC@Ch/Sa/Paa-mvFA.[67]
Based on the assumption that activated macrophages are the 
primary target to manage rheumatoid arthritis (RA),[78] Kumar 
et al.[79] investigated the ability of the pH sensitive glycol ChNPs 
to efficiently target macrophages by anchoring FA on NPs 
surface. Indeed, activated macrophages involved in RA highly 
expressed FA receptor β (FA-Rβ) on their surface.[80] Moreover, 
glycol ChNPs were investigated for the release of methotrexate 
(MTX) in the acidic environment of the RA.[81] MTX is the main 
drug employed to manage RA, but its use is associated with 
serious side effects such as renal disfunction and gastrointes-
tinal deficiency.[82] Therefore, loading MTX in NPs is advanta-
geous to lower its side effects and increase its therapeutic effi-
ciency through a targeted action.[83] NPs were prepared by nan-
oprecipitation and FITC was conjugated to FA-modified glycol 
ChNPs. In vitro cellular uptake studies of fluorescent NPs were 
performed on both murine macrophage-like RAW264.7 cells, 
which were stimulated or not with LPS to induce the expres-
sion of FA-Rβ, and activated peritoneal macrophages (Mφ), har-
vested from mice treated with sodium thioglycolate.[84] Stronger 
fluorescence was recorded in LPS-treated RAW264.7 cells and 
Mφ compared to LPS-untreated RAW264.7 cells (which do not 
express the FA-Rβ), indicating the targeting efficiency of FA-
modified FITC@glycol ChNPs.[85]
2.11. Sialic Acid Groups
In a study conducted by Wang et  al.,[86] the surface of ChNPs 
was grafted with 4-carboxyphenylboronic acid (CPBA). This 
was used as a targeting agent for tumor cells overexpressing 
sialic acid groups on their surface, forming boronated ester 
and enhancing the targeting activity of antitumor agents.[87,88] 
CPBA ChNPs were labeled with FITC for cell uptake studies 
and loaded with doxorubicin (Dox). ChNPs with no CPBA and 
free Dox were taken as control. The uptake was tested in three 
cellular models: human neuroblastoma SH-SY5Y cells, human 
liver carcinoma HepG2 cells, and mouse hepatoma H22 cells. 
To investigate the cellular distribution of NPs, all three cell lines 
were used as a monolayer and stained with Lyso-Tracker Red, a 
lysosomal/endosomal marker. Cells were then treated with fluo-
rescent NPs and a lysosomal and endosomal co-localization of 
NPs was noticed, suggesting that the cellular uptake followed the 
endocytic pathway. Moreover, CPBA-functionalized NPs induced 
stronger fluorescence than noncoated NPs, indicating that phe-
nylboronic acid enhanced the internalization of NPs. The intra-
cellular delivery of Dox, emitting weak red fluorescence, was also 
investigated. Confocal images indicated a stronger red signal in 
the cytoplasm and nuclei in cells treated with CPBA-coated NPs. 
This is because more Dox was delivered to tumor cells owing to 
the presence of the targeting agent. SH-SY5Y cell line was then 
used for 3D culture multicellular spheroids (MSC), representing 
the avascular region of the tumor. After treatment with NPs, con-
focal images of the MSC indicated that Dox-loaded CPBA ChNPs 
induced a stronger FITC signal on the MSC periphery, compared 
to uncoated NPs and free Dox. Moreover, Dox fluorescence was 
detected in almost all the MSC. This supported the finding that 
the former permeated much deeper, accumulated to a greater 
extent, and delivered more Dox into MCS than the latter and free 
Dox (Figure 6). Finally, mice were injected with murine H22 cells 
to develop the tumor. Fluorescent NPs were then injected into 
the H22 tumor-bearing mice, which were sacrificed after 24 h. 
The tumor, along with its blood vessels, was extracted and sliced 
into 6  µm sections for staining. In the confocal microscope, 
green fluorescent signals corresponding to FITC@ChNPs were 
detected in the tumor sections: CPBA ChNPs were identified 
in the whole tumor far from the blood vessels, while uncoated 
ChNPs were observed just around the blood vessels. This indi-
cated that CPBA ChNPs can permeate the blood vessels and 
accumulate in the tumor. Further experiments were performed 
by Wang et al.[86] concerning the antitumor activity of NPs. They 
found that Dox-loaded CPBA ChNPs also had the advantage of 
limiting the tumor growth in tumor-bearing mice, compared to 
the controls (free Dox and uncoated NPs).
2.12. Biocompatibility of Chitosan-Based NCs
It is well known that, upon intravenous (i.v.) administration, 
most of the polymeric NPs fail to reach the target site for the 
delivery of their cargo, due to their rapid removal by the immune 
Figure 5. In vitro targeting efficiency of FA-coated FITC@ChNPs toward 
HeLa cells. NPs are then injected into tumor-bearing mice for in vivo 
targeting efficiency testing.
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system.[89] This consists of the reticuloendothelial system (RES), 
made of macrophages situated in various organs such as the 
spleen, liver, and lymph nodes, which constitute the MPS.[90]
Due to the positively charged surface, ChNPs perform strong 
interactions with serum proteins, leading to NPs aggregation 
and clearance.[91] Therefore, several investigations have been 
performed to assess the biocompatibility of Ch-based NCs and 
evaluate their suitability as an in vivo drug delivery system and 
FITC has played a pivotal role in showing the fate of polymeric 
NPs in several studies.
2.13. Micelles
The biocompatibility of PEG-coated FITC@Ch-based micelles 
was assessed in RAW264.7 cells.[92] To quantify their cel-
lular uptake, chitosan was labeled with FITC before forming 
micelles and cells were incubated with the fluorescent micelles 
up to 24 h. PEG-uncoated micelles were used as a control and 
the cell lysate was used for quantitative study using the fluorim-
eter. Results showed that, compared to the control, the presence 
of PEG on the micelles’ surface significantly decreased the cel-
lular uptake by macrophages, in turn reducing their clearance. 
This suggested that PEG-coated Ch-based micelles could act as 
an in vivo drug delivery carrier.[92]
Huo et al.[93] generated micelles composed of an amphiphilic 
derivative of low MW chitosan, the N-octyl-N, O-carboxymethyl 
chitosan (OCmCh). OCmCh micelles were conjugated to FITC 
and intravenously injected into healthy mice, which were then 
sacrificed at specific time points. Blood and homogenized MPS 
organs were centrifuged, and the supernatant was analyzed by 
fluorimetry to estimate FITC@OCmCh micelles concentration. 
Results showed that the concentration of micelles in plasma 
was very high (≈98% of dose), in liver was very low (≈10% of 
dose) while in the remaining organs was negligible (≈0.5% of 
dose). These results suggested that OCmCh micelles had a 
prolonged time in the blood circulation, avoiding the MPS for 
removal, hence representing a potential i.v. injectable carrier 
for hydrophobic drugs.
2.14. Nanoparticles
Research suggests that the blood circulation time of NPs can 
be prolonged by attaching them to the surface of erythro-
cytes[94,95] In this respect, Fan et  al.[96] explored the possibility 
for FITC@ChNPs to escape the RES by assessing their bio-
compatibility with erythrocytes, so to be used as a vascular 
drug delivery system. Low MW chitosan was labeled with FITC 
and used to generate NPs by ionic gelation.[97] The stability of 
FITC@ChNPs in isotonic sodium chloride medium, needed 
for erythrocytes culture, was assessed by CLSM and images 
showed that NPs were well dispersed up to 5 h incubation in 
this medium. Hemolysis and modifications of erythrocyte mor-
phology were the parameters observed to study the compat-
ibility of NPs with erythrocytes. Erythrocytes, incubated with 
FITC@ChNPs were observed at the CLSM and images showed 
that NPs were anchored to the membrane of erythrocytes, even 
after the washing steps, probably due to electrostatic interac-
tions between the negatively charged erythrocytes and the posi-
tively charged ChNPs[98] Indeed, study of the hemolysis showed 
that the erythrocyte membrane was slightly damaged by treat-
ment with NPs, although this had no impact on the erythrocyte 
morphology.[96]
The interaction of ChNPs was assessed in RAW264.7 cells to 
understand the retention time of such NPs in the body.[99] Fol-
lowing chitosan labeling (MW of 50 kDa and DDA of 90%) with 
FITC, NPs were generated by ionic gelation, resulting in a size 
of about 250  nm and charge of +20  mV. Intracellular fluores-
cence indicating the uptake of NPs was dependent on the con-
centration and time of exposure of NPs, reaching the satura-
tion at 500 µg mL−1. Along with clathrin and caveolae-mediated 
endocytosis, phagocytosis was proposed as an internalization 
mechanism, typical of macrophage (Figure 7). Since the cave-
olar endocytic vesicles diameter is lower than 80 nm and NPs 
formulated in this study had a size of 250 nm, the authors con-
cluded that CME and phagocytosis were potential mechanisms 
for the uptake of FITC@ChNPs by RAW264.7 cells. Chemical 
inhibitors for CME (sucrose) and phagocytosis (O-phospho-
l-serine) were used to determine the uptake pathway. It was 
shown that treatment with sucrose inhibited the uptake of 
NPs, suggesting that the uptake pathway undertaken by NPs 
was mainly CME. However, treatment with O-phospho-l-serine 
induced inhibition of the uptake after 8 h treatment, suggesting 
the phagocytic pathway was undertaken for NPs larger than 
500 nm, perhaps due to agglomeration with time.[99]
Further, Zubareva et al.[100] investigated the influence of the 
surface charge of ChNPs on their fate and cellular uptake by 
MIAPaCa-2 cells and RAW264.7 cells. To this end, positively 
charged ChNPs, composed of hexanoyl chitosan (HCh), and 
negatively charged ChNPs made of succinoyl chitosan (SCh), 
were generated. Chitosan was labeled with FITC so to obtain 
FITC@HChNPs and FITC@SChNPs. FITC@ChNPs along 
with the corresponding polymers were taken as control. Experi-
ments were carried out in complete cell culture medium sup-
plemented with 10% fetal bovine serum (FBS), containing 
a high concentration of negatively charged albumin. This 
induced HChNPs to absorb albumin on their surface so to 
decrease the surface charge from +35 to −13 mV and increase 
the size of NPs by 20%. Instead, SChNPs being negatively 
charged, did not modify their surface charge (−28  mV), but 
decreased the size by 30%, for unspecified reasons.[100] The 
impact of the surface charge on the cellular uptake of pan-
creatic cells was investigated by CLSM. Images showed that 
Figure 6. Tumor section showing the location of CPBA-coated and 
uncoated FITC@ChNP carrying Dox.
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FITC@ChNPs and chitosan adhered to the cellular surface as 
early as 2 h. FITC@SChNPs bound more efficiently than the 
corresponding polymer, probably due to their size, which fur-
ther enhanced endocytosis. FITC@HCh and the corresponding 
NPs followed a similar trend as SChNPs. The intracellular 
fate of fluorescent HChNPs and SChNPs in MIAPaCa-2 cells 
was tracked by labeling the intracellular organelles. FITC@
HChNPs were found in cell membrane and endosomes after 
2 h incubation, and then in the mitochondria after 12 h incuba-
tion. FITC@SChNPs were co-localized in endosomes after 2 h 
incubation and with lysosomes after 12 h incubation. Further, it 
was noticed that HChNPs co-localized with the cell membrane 
for the entire incubation time, while SChNPs were engulfed 
very quickly, via the endosomal pathway. However, a different 
trend was observed in macrophages, which are known to inter-
nalize chitosan by the mannose receptor.[101] Indeed, when 
analyzing the intracellular fate of fluorescent HChNPs and 
SChNPs in RAW264.7 cells, it was noticed that the uptake of 
positively charged HChNPs was more efficient in macrophages 
than epithelial cells and NPs were co-localized with mitochon-
dria and lysosomes. Instead, negatively charged SChNPs were 
found only in lysosomes of macrophages, as for epithelial cells.
Zhang et  al.[102] explored the possibility to coat the surface 
of FITC@ChNPs with the polyanionic poly (methacrylic acid) 
(PMA) to increase ChNPs stability in the blood, along with 
enhancing the cellular uptake and endosomal escape. The 
chemotherapeutic agent, 10-hydroxycamptothecin, was encap-
sulated in the NPs. Uncoated FITC@ChNPs generated by ionic 
gelation were taken as control. To understand the interaction of 
PMA-coated and -uncoated FITC@ChNPs with blood compo-
nents, NPs were injected into the tail vein of Sprague–Dawley 
mice. Evaluation of the concentration of fluorescent NPs in the 
plasma revealed that PMA-coated NPs had a higher stability 
than uncoated NPs, hence requiring less frequent doses.[103] 
Furthermore, evaluation in HepG2 cells showed that the cel-
lular uptake was significantly higher at pH 6.5 than pH 7.4 and 
this was attributed to the fact that the surface charge of NPs 
becomes negative at physiological pH, limiting the cellular 
uptake.[104] Using the same pH conditions, FITC@NPs were 
incubated with cells at increasing incubation time to evaluate 
the endosomal escape. CLSM images indicated that, after 2 h 
incubation, PMA-coated NPs were quickly engulfed by HepG2 
cells and sequestered by endosomes at pH 6.5 as shown by the 
yellow fluorescence (resulting from the green signal of FITC 
overlapped with the red signal of LysoTracker Red, used to 
stain lysosomes). After 3 h incubation with PMA-coated NPs, 
the red fluorescence of endosomes gradually disappeared, 
indicating their degradation following NPs escape. At pH 7.4, 
the fluorescence of PMA-coated FITC@ChNPs was localized 
mainly around the cells, indicating a weak cellular uptake. Alto-
gether, these results suggested that PMA-coated FITC@ChNPs 
could be used for clinical applications since they showed a 
prolonged circulation time in the blood and endosomal escape 
properties.[102]
3. The Use of Fluorescent Chitosan-Based NCs in 
Various Techniques
3.1. Diaminobenzidine Photoconversion
Diaminobenzidine (DAB) photoconversion was used to investi-
gate the intracellular journey of FITC@ChNPs in rat neuronal 
B50 cells.[105] DAB photoconversion correlates fluorescence and 
transmission electron microscopy (TEM), allowing the visu-
alization of small FITC@ChNPs and tracking their intracel-
lular fate. For fluorescence studies, cells were incubated with 
FITC@ChNPs and stained for DNA (Hoechst 33258, blue), to 
investigate a possible intranuclear location of NPs, and plasma 
membrane (PHK26, red), to explore the NPs cellular uptake. 
Fluorescence studies demonstrated that NPs were successfully 
internalized by neuronal cells and some of them were found 
freely in the cytoplasm. This finding is relevant for the pharma-
cological activity of the NPs, as it suggests that NPs escaped the 
endosomes, confirming their suitability for drug delivery directly 
in the cytoplasm of neurons. Most of the NPs were located peri-
nuclearly, ensuring potent drug delivery around the nucleus. 
The suggested internalization mechanism was via endocytosis 
since FITC@ChNPs were also co-localized with the plasma 
membrane (Figure 8).[105] These results were confirmed by incu-
bating B50 cells with DAB and irradiating them with lamps suit-
able for FITC excitation. The reaction product rendered the NPs 
visible under the TEM, appearing dark and homogenously dis-
tributed. The images showed that the NPs were mostly located 
in vacuoles, next to the cellular membrane, and free in the cyto-
plasm and in the perinuclear region. Some NPs were also found 
in multivesicular bodies suggesting that CME was still taking 
place, inducing lysosomal degradation of the NPs.[16,105] To con-
clude, DAB photoconversion helped to confirm the entrance of 
NPs into neuronal cells and suggested that ChNPs may be a 
suitable intracellular drug delivery system in vivo.[105,106]
3.2. Layer-by-Layer (LbL) Assembly Technique
Calcagno et  al.[107] assessed the cellular uptake of FITC@
ChNCs generated through an emerging technique known as 
“LbL assembly.”[108] This method has been widely employed to 
assemble films by electrostatic interactions, for use in many 
applications, such as the generation of polyelectrolyte mul-
tilayer capsules for poorly water soluble drug delivery.[109,110] 
However, the biostability of the interactions in the oil-in-water 
nanoemulsions generated by this method is very weak in the 
physiological environment, representing a relevant drawback 
Figure 7. Phagocytosis pathway taken by a large FITC@ChNP in 
macrophages.
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for biomedical applications.[107,110] Thus, to improve the biosta-
bility, a lipophilic NC composed of natural materials such as 
soybean oil and egg lecithin was coated with polymeric mul-
tilayer film made of thiol, allylic-modified glycol FITC@Ch, 
and heparin.[107] Cell uptake studies were carried out in murine 
brain endothelial bEnd.3 cells, which were then analyzed for 
fluorescence intensity by CLSM. Images showed that fluores-
cent nanoemulsions were efficiently taken up by cells after 24 h 
incubation, with the green spots localized mainly around the 
nuclei. Further biostability and cytotoxicity studies were per-
formed, which proved the biocompatibility and stability of the 
nanoemulsions prepared by the LbL method. Altogether these 
results suggested that the resulting nanocapsules could be effi-
ciently used in drug delivery.[107]
In the context of tumor imaging, Hu et al.[111] employed the 
LbL technique to form NPs composed of FITC@Ch conju-
gated with PEG and FA, as targeting ligand of tumor cells,[112] 
while the nanocore was made of perfluorooctyl bromide. 
The targeting ability of fluorescent NPs was assessed in vitro 
employing the hepatoma Bel7402 cells (FA-R positive) and 
healthy liver L02 cells (FA-R negative). The cellular uptake was 
detected as a measurement of fluorescence intensity. Results 
from fluorescence microscopy indicated that the fluorescence 
intensity was stronger in Bel7402 cells than L02 cells, due to the 
presence of the FA-R in tumor cells. Flow cytometry analysis 
confirmed these results and was able to quantify the intracel-
lular FITC. It was found that almost 97% of Bel7402 cells (see 
62% of L02 cells) were FITC-positive. These results indicated 
that the cellular uptake of hepatoma cells was enhanced by the 
presence of the folate ligand on NPs, making this novel system 
suitable for ultrasonic molecular imaging of tumors overex-
pressing the folate receptor.[111]
3.3. Pulsed Ultrasound
Pulsed ultrasound (PU) is a noninvasive therapeutic technology, 
using the delivery of pulsed mechanical waves.[113] PU shows 
several applications such as clinical diagnostics, cancer therapy, 
wound and bone fracture healing.[114,115] PU has also been found 
to increase the proliferation of osteoblasts in vitro.[116] Low-inten-
sity PU can be used as an adjuvant for conventional drug delivery 
since it was shown to improve the delivery efficiency of drug car-
rier systems, and in turn the therapeutic efficiency of the drug.[117]
In this regard, Wu et  al.[118] employed FITC@ChNPs to 
investigate their impact of cell viability and cellular uptake of 
osteoblasts when used in conjunction with PU. In vitro cellular 
uptake and cell viability studies were carried out in murine 
pre-osteoblasts, MC3T3-E1 cells. After 30  min incubation of 
cells with FITC@ChNPs, cells received the PU treatment 
using an ultrasound transducer. Confocal images showed that 
upon treatment with PU, FITC@ChNPs were taken up more 
efficiently than in the control (i.e., nonirradiated cells). Flow 
cytometry was used to assess the cell viability upon treatment 
with NPs and PU, by means of propidium iodide (PI), a red dye 
which does not permeate the cellular membrane of live cells. 
PU treatment alone did not cause much damage to the mem-
brane of cells. Treatment of FITC@ChNPs alone induced a very 
strong green fluorescence, suggesting a high affinity of ChNPs 
toward the cells, while the PI signal significantly decreased 
compared to that for PU treatment. Upon treatment of both 
FITC@ChNPs and PU, the FITC signal increased dramatically, 
suggesting that a larger number of NPs were engulfed by the 
cells. Since most cells were both FITC and PI positive, it was 
deduced that the disruption of cellular membranes was due to 
their association with ChNPs.
4. Drug-Loaded Chitosan-Based NCs
4.1. Chemotherapeutic Agents
MTX is a chemotherapeutic agent and immune system sup-
pressant, widely used in the treatment of many malignancies 
and potentially useful to treat brain tumors.[119] However, its 
utility for brain tumor treatment is limited due to the pres-
ence of the BBB, possessing efflux transport systems such as 
the P-glycoprotein that pumps out MTX.[120] To overcome this 
limitation and deliver MTX to the brain, Trapani et al.[119] encap-
sulated MTX in glycol ChNPs, with increased water solubility 
properties, coated with Tween 80. The coating with Tween 
80 was shown to increase the transport of drug-loaded NCs 
through the BBB by adsorbing apolipoproteins, which are rec-
ognized by specific receptors on the BBB.[121] In vitro cellular 
uptake studies were performed on the MDCKII-MDR1 cell 
monolayer and glycol chitosan was labeled with FITC prior 
to NPs formation. Cells were incubated with the NPs suspen-
sions. The efflux system was assessed by adding the inhibitor, 
VER, before NPs treatment. Upon VER treatment, green fluo-
rescent NPs appeared on the cell membranes. The trypan blue 
technique was used to detect the fraction of Tween 80-coated 
glycol ChNPs engulfed by cells. CLSM images showed that sig-
nificantly more Tween 80-coated NPs were internalized than 
uncoated ones, suggesting that these NCs can enhance the in 
vitro transport of MTX through the BBB.
The cellular uptake of PEG-coated FITC@Ch-based micelles 
was investigated in healthy liver cells (BRL-3A) and liver tumor 
cells (HepG2).[92] Chitosan oligosaccharide, grafted with stearic 
acid was used to form self-assembled micelles, which contained 
a hydrophobic core where the poorly water-soluble mitomycin 
C could be encapsulated.[92,122] PEG-free micelles were used 
as control and the cell lysate was analyzed by fluorimetry for 
quantitative study. Results showed that the presence of PEG 
Figure 8. Intracellular localization of FITC@ChNPs in the neuron’s cell 
body: NPs mainly localized perinuclearly, then in the cytoplasm, finally in 
the lysosomes.
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on micelle surfaces did not affect the cellular uptake by both 
healthy and cancer cells, albeit the conjugation with a specific 
ligand for cancer cells could increase their cellular uptake while 
decreasing that of healthy cells.[92]
Polyoxometalates (Poms) are novel therapeutic agent proto-
types constituted by transition metal oxide clusters and possess 
antibacterial, antiviral, and antitumorigenic properties.[123] To 
reduce the potential side effects associated with Poms’ use,[124] 
Geisberger et  al.[125] generated a novel nanocomposite system 
composed of Poms and trimethyl chitosan (TmCh). TmCh is a 
derivative of chitosan, soluble in neutral and slightly alkaline 
solutions, and its positive charges allow a stronger electrostatic 
interaction with the negatively charged Poms and a higher cel-
lular uptake than chitosan.[125] Cellular uptake studies were per-
formed on HeLa cells using FITC@NPs and a microplate lumi-
nometer was used to detect the fluorescence. Carboxymethyl 
chitosan (CmCh) NPs were used as control.[126] Cells were incu-
bated with fluorescent NPs at different doses and incubation 
times. Results showed that the incorporation of FITC@TmCh/
Poms NPs was higher than the control, since the uptake of 
positively charged NPs occurred at high extent than negatively 
charged NPs.[125,127] Further, HeLa cells were treated with chlor-
promazine, blocking the CME and this treatment did not affect 
the cellular uptake of FITC@TmCh/Poms NPs, suggesting that 
it occurred through different routes such as micropinocytosis 
and caveolae-mediated transport.[128]
Docetaxel is a high potent antitumor agent whose clinical 
applications are limited due its poor solubility in water and 
severe side effects. Poly(D, L-lactide-co-glycolide) (PLGA) is a 
biopolymer widely used in NCs formulations but characterized 
by a negative surface charge that does not allow cellular absorp-
tion.[129] However, polycationic polymers such as chitosan can 
be used to modify the surface of PLGA, overcoming the cellular 
absorption limitations. Asthana et al.[129] assessed the feasibility 
to formulate nanosized docetaxel carriers for cancer therapy, 
based on PLGA NPs modified with chitosan, labeled with FITC 
to perform cellular uptake studies. The fluorescent marker 
enabled visualization of NPs in in vitro studies using a human 
breast cancer cell line, MCF-7. Flow cytometry data showed that 
the cellular internalization of NPs was faster for NPs coated 
with chitosan than uncoated, suggesting some potential for chi-
tosan-coated PLGA NPs to deliver docetaxel effectively to cancer 
cells.[129]
Paclitaxel (Ptx) is a potent chemotherapeutic agent, success-
fully used to treat many tumors, such as breast and ovarian 
cancers.[71] However, Ptx is poorly applied in the clinic due to 
its poor water solubility and high cellular toxicity following 
i.v. administration.[130] The employment of several strategies 
such as targeted delivery using FA (highly expressed on many 
human cancer cells, e.g., breast cancer)[131] and encapsulation 
in NCs can overcome these limitations.[130] FITC@ChNCs have 
shown to play a key role in enhancing Ptx delivery to tumors. 
For instance, Li et  al.[132] tested the efficiency of ChNPs to act 
as a sustained delivery system of Ptx. This was encapsulated 
in the NPs formed by solvent evaporation and emulsification 
crosslinking method, obtaining spherical NPs with a smooth 
surface and an average size of 110  nm. FITC was conjugated 
with ChNPs for confocal in vitro uptake studies against the 
human ovarian cancer A2780 cell line. Cells were incubated 
with drug-loaded NPs at different incubation times and a 
week green fluorescence appeared inside the cells after 1 h, 
increasing after 12 h of incubation. The slow increase denoted 
that the cellular uptake of Ptx-loaded NPs was mediated by non-
specific absorptive endocytosis.[132]
Park and Cho[133] employed glycol chitosan to form self-
assembled NPs encapsulating Ptx. The cellular uptake of Ptx-
loaded NPs was assessed by labeling chitosan with FITC and 
using several cell lines including HeLa, SCC7 (murine squa-
mous cell line), and NIH3T3 (murine fibroblast cells). Cells 
were treated with the suspension of fluorescent NPs and the 
cellular uptake was quantified by flow cytometry. Results 
showed that NPs were rapidly engulfed by NIH3T3 and SCC7 
cells due to nonspecific interactions between chitosan and the 
plasma membrane. The dynamics of exocytosis and endocytosis 
was evaluated in HeLa cells by incubating the cells with NPs, 
followed by their removal. Results showed that the amount of 
exocytosed NPs decreased with increased pre-incubation time, 
suggesting that exocytosis is an endocytosis-dependent process 
and a limiting factor for the internalization of NPs.[133]
In a study performed by Rezazadeh et al.,[130] Ptx was encap-
sulated in polymeric micelles composed of tocopherol succinate 
(Ts), forming the hydrophobic core and enveloping the drug, 
and chitosan, forming the hydrophilic shell. Micelles were 
also decorated with a targeting ligand such as FA and PEG, to 
increase their in vivo stability.[134–136] Cell uptake studies were 
performed on a murine breast carcinoma cell line, 4T1 cells. 
Chitosan was labeled with FITC while generating micelles so 
to obtain FA/PEG-coated FITC@TsCh micelles, using uncoated 
micelles as a control. Following 12 h incubation with the 
micelles, cells were observed under a fluorescence microscope 
at given time intervals. Results showed that, following incuba-
tion with the control, the intracellular fluorescence intensity, 
and hence the cellular uptake, was time dependent. In con-
trast, following incubation with FA/PEG-coated FITC@TsCh 
micelles, a very rapid cellular uptake was recorded as early as 
after 2 h incubation, owing to the FA/PEG coating. Further, cell 
viability studies confirmed the cytotoxic effect of Ptx-loaded FA/
PEG-coated FITC@TsCh micelles on 4T1 cells.[130]
Following the same methodology, Cheng et  al.[71] encapsu-
lated Ptx in polymeric micelles decorated with FA but based 
on chitosan modified with cholesterol (Cho), as an amphi-
philic co-polymer.[137] To perform cell uptake studies, chitosan 
was labeled with FITC so to obtain FA-coated FITC@Ch/
Cho micelles. FITC solution was used as a control. The target 
ability of the micelles was assessed in two cell lines, expressing 
or not the FA-R, HeLa, and A549 cells, respectively. The FA-R 
was stained with TRITC (red) and its presence on HeLa cells 
was confirmed by CLSM. Following treatment with FA-coated 
FITC@Ch/Cho micelles, the fluorescence intensity was found 
to be higher in HeLa cells than A549 cells and the control. 
This result suggested that FA-coated FITC@Ch/Cho micelles 
showed efficient targeting ability, classifying them as a prom-
ising candidate for targeted antitumor activity.[71]
Dox is a well-known topoisomerase inhibitor widely used 
to halt tumoral growth. However, it has very low sensitivity 
against many cancer cells such as liver or stomach.[138] To 
enhance Dox’s antitumor properties, while reducing its 
side effects, several approaches have been developed using 
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FITC@ChNCs. These approaches make use of micelles, 
nanocomposites, and NPs.
Son et al.[139] encapsulated Dox in self-aggregates constituted 
by glycol chitosan. Chitosan was labeled with FITC to assess 
NPs accumulation in the tumor site by EPR effect. Male Fisher 
344 rats were injected with mesothelioma II45 cells to develop 
the tumor. The suspension of fluorescent NPs was then inoc-
ulated in tumor-bearing rats and at given intervals (1, 3-, and 
8-days post-injection), rats were sacrificed. The blood, tumor, 
and main organs were isolated. Organs were homogenized, 
lysed, centrifuged, and the supernatant was analyzed using a 
spectrophotometer. Results showed that a higher proportion 
of the NPs was found in kidney, tumor, and liver than other 
tissues. In the tumor, the concentration of NPs increased with 
the incubation time. Moreover, the concentration of NPs in the 
blood was found to be very high throughout the 8 days post-
injection, suggesting that NPs were very stable in the blood and 
accumulated in the tumor through the EPR effect.[139]
Hu et  al.[140] encapsulated Dox in polymeric micelles made 
of stearic acid-grafted ChOs, with improved water solubility 
and reduced MW.[141] Cellular uptake was assessed in model 
cancer cells including A549, Lewis lung cancer cell (LLC), 
and human ovarian carcinoma cell line (SKOV3) by labeling 
ChOs with FITC, while generating self-assembled micelles. 
Dox was encapsulated by adding glutaraldehyde and forming 
shell crosslinked micelles. After incubating cells with micelles, 
cells were harvested, lysed, centrifuged, and the fluorescence 
in the supernatant was detected by fluorimetry. It was shown 
that owing to their spatial structure with multi-hydrophobic 
core, micelles were engulfed by the tested cancer cells, but the 
cellular uptake was higher in LLC and SKOV3 cells than A549 
cells and increased with the incubation time. The encapsulation 
of Dox did not alter the micelles’ properties, including size and 
cellular uptake ability.[140]
Xie et  al.[142] encapsulated Dox in polymeric micelles to 
enhance its transport across the BBB. The BBB is characterized 
by TJs, which limit the paracellular transport of any harmful 
substance and an overexpression of active efflux systems that 
prevent chemotherapeutic agents such Dox or other substances 
to reach the brain.[143] In this study,[142] stearic acid was grafted 
to low MW chitosan, forming self-assembled micelles widely 
used for the delivery of therapeutic actives or genes.[141,144] Cell 
uptake studies were carried out on bEnd.3 cells, an in vitro 
model of BBB. To allow micelles visualization, Sa/Ch was 
labeled with FITC and incubated with cells. The cellular uptake 
was analyzed by fluorescence microscopy and found to occur as 
early as 30 min of incubation, gradually increasing along with 
the incubation time, suggesting that endocytosis was the main 
mechanism involved in the cellular uptake.[142]
FITC@Ch was employed in the formation of magnetic gra-
phene oxide (mGO)/sodium alginate (Sa)/chitosan (FITC@
mGO/Sa/Ch) nanocomposites.[145] This system could act as 
an efficient NC for drug delivery.[145,146] The cell uptake of Dox-
loaded FITC@mGO/Sa/Ch nanocomposites was evaluated by 
CLSM in A549 cells, and the magnetic targeting of the nano-
composites was tested. In the absence of a magnet, there was 
some nanocomposite uptake by A549 cells through endocytosis, 
gathering mainly in the cytoplasm; when a magnet was placed 
below the culture dish, CLSM images indicated a stronger green 
fluorescence given by the presence of FITC@nanocomposites, 
suggesting that the magnet enhanced the cellular uptake. This 
work classified Dox-loaded FITC@mGO/Sa/Ch nanocomposite 
as an eligible candidate for targeted drug delivery of Dox.[145]
Masarudin et  al.[147] used optimized FITC@ChNPs as a 
delivery system for Dox. Fluorescent NPs were produced by 
ionic gelation and refined to produce homogenous small NPs 
(< 100  nm); these were tested for efficient accumulation in 
human kidney cancer cells (786-O). Confocal images showed 
that a significant intracellular uptake of NPs (perinuclear or in 
the cytoplasm) appeared after 6 h treatment. However, further 
in vivo studies are still to be performed.
In the context of targeted tumor delivery system, a water-sol-
uble derivative of chitosan, CmCh was employed in the genera-
tion of NPs as Dox carrier.[148] The targeted ability was conferred 
by functionalizing its structure with FA, whose receptor is 
overexpressed in many types of cancer cells.[149] Dox-loaded, FA-
modified CmCh NPs were then labeled with FITC. Cell uptake 
studies were performed on cancer cells (HeLa and B16F1 cells) 
and healthy cells (NIH3T3 and L929 cells).[148] Flow cytometry 
analysis showed that the fluorescent intensity was stronger in 
cancer cells than healthy cells. This suggested the high tar-
geting efficiency of NPs conferred by the folate functionaliza-
tion which receptor-mediated endocytosis in cancer cells.[148]
More recently, FITC-labeling was used by Wang et  al.[150] 
in the formulation of Dox-loaded NPs based on CmCh. 3-car-
boxyphenylboronic acid (3-CPBA) was linked to the surface of 
NPs as a tumor targeting agent.[87,88] Following the encapsula-
tion of Dox, uniform and spherical NPs were obtained. Cellular 
uptake (infiltration and distribution) of FITC@CMChNPs was 
explored in MSC (SH-SY5Y) by CLSM. A very strong green 
(FITC@NPs) signal was detected in the periphery of MSC 
while Dox signal (red) diffused from the periphery to the center 
of the MSC after 24 h incubation. Finally, a yellow signal, cor-
responding to the overlap of FITC and Dox was also found in 
the MSC, suggesting that NPs efficiently gathered in the MSC, 
releasing Dox in situ (Figure 9).
4.2. Various Other Drugs
FITC@ChNPs were investigated as a potential brain delivery 
system of the neurotransmitter dopamine for the treatment 
of neurodegenerative disorders.[151] The Madin–Darby canine 
kidney mdr1-transfected MDCKII-MDR1 cell monolayer was 
used as an in vitro model of the BBB.[152] Following adsorp-
tion of dopamine on the external surface of NPs, the interac-
tion of NPs with the cell line was assessed by flow cytometry. 
A gradual increase in intensity was detected after 180  min 
incubation time. Moreover, stronger fluorescence was seen in 
the cytoplasm, but none in the nucleus, indicating that NPs 
were internalized by the cells. Further studies supporting this 
funding showed an increased fluorescence in the basolateral 
chamber owing to the presence of FITC@NPs. The authors 
concluded that the enhancing in permeability was such that the 
experiment supported the hypothesis that ChNPs loaded with 
dopamine activated the transcellular pathway (Figure  10). The 
transport of dopamine to the brain has also been investigated 
using chitosan derivatives-based NPs for nasal administration, 
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as a noninvasive method to overcome the BBB.[153] In this study, 
NPs were formed based on glycol chitosan. NPs were generated 
through ionic gelation by using sulfobutylether-b-cyclodextrin 
(SBE-b-CD), which enhances the dopamine stability.[153] Biodis-
tribution studies were performed on Wistar rats by nasal admin-
istration of FITC@NPs. Detection of the fluorescence associated 
with NPs indicated that the NPs administered by this route can 
reach the brain through the ipsilateral hemisphere.[153,154]
Zidovudine has been approved by the FDA for the treat-
ment of renal infections.[155] However, it is characterized by a 
very short circulation time and poor kidney accumulation.[156] 
To overcome these limitations, Liang et  al.[157] formed a drug-
carrier conjugate composed of zidovudine and oligomers of 
chitosan (Cos) with improved water solubility and high DDA 
(98%).[158] Indeed, it has been shown that a 50% N-acetylated 
low MW chitosan-prednisolone conjugate was able to increase 
the renal uptake of the drug by ten times.[159] In addition, 
it was found that the renal uptake increased at high DDA of 
chitosan.[160] For biodistribution studies, Cos was labeled with 
FITC and the formulations were administered to Wistar rats. 
Tissue samples (liver, spleen, brain, heart, lungs, and kidney) 
were collected for fluorescence imaging, which indicated a high 
accumulation of this carrier in the kidneys.[157]
In a study conducted by Jung et al.,[161] FITC@ChNPs were 
adsorbed onto a nanofibrous wound dressing as a drug delivery 
system of fucoidan (known to promote wound healing) and 
then tested for uptake by primary rat fibroblasts. NPs, formu-
lated via ionic gelation, resulted in a particle size of 40  nm, 
small enough to permeate within nanofibers. Moreover, NPs 
adhered to nanofibers by weak hydrophilic and van der Waals 
interactions and were able to detach in the aqueous phase of 
the culture medium. Indeed, FITC-@ChNPs were successfully 
infiltrated into the fibroblasts upon exposure. This was proven 
by the fact that the fluorescence remained inside the fibroblasts 
despite following washes.[161]
Prednisolone is a hydrophobic glucocorticoid widely used to 
treat ulcerative colitis.[162] Due to the importance of delivering 
therapeutics to the diseased tissue, Zhou et  al.[163] conjugated 
prednisolone to a novel drug delivery system: nanogels consti-
tuted by FITC@glycolCh modified with succinyl groups con-
ferring a negatively charged surface (−28  mV). This system 
assumed that negatively charged molecules accumulate in 
the diseased colonic membrane,[164] and do not interact with 
the healthy gastrointestinal (GI) mucosa.[165] Since ulcerative 
colitis is considered as an autoimmune disease, cellular uptake 
studies were performed on RAW264.7 cells, with the help of 
the fluorescence probe FITC, introduced in the nanogel. FITC 
free in solution was taken as control. CLSM images showed 
that fluorescent nanogels were allocated in the cytoplasm, indi-
cating an efficient uptake. LPS was also added to activate the 
macrophages and no impact on cellular uptake was recorded, 
suggesting that nanogels were engulfed by cells independently 
on their activation and demonstrating their potential for ulcera-
tive colitis treatment.[163]
5. The Use of Fluorescent Chitosan-Based NCs in 
Emerging Therapies
5.1. Photodynamic Therapy (PDT)
PDT is an emerging targeted treatment for tumors and con-
sists in the delivery and irradiation of photosensitizers so that 
highly reactive oxygen species are produced, causing tumor 
cell death.[166] Unfortunately, the major problem with PDT 
is that most of the photosensitizers in clinical use are hydro-
phobic inducing self-aggregation in physiological media.[167] To 
increase the water solubility and to improve the tumor accu-
mulation of photosensitizers, several NCs based on FITC@Ch 
have been developed.[168]
In the attempt to generate tumor-targeting FITC@ChNPs 
for PDT, Lee et  al.[169] employed the water-soluble glycol chi-
tosan (GCh), self-assembled with hydrophobic molecules 
such as 5β-cholanic acid.[170] The resulting NPs were shown 
to prolong the bioavailability of cancer drugs and targeting 
effect against tumors.[171] Indeed, the hydrophobic core made 
of 5β-cholanic acid could accommodate chemotherapeutic 
agents such as chlorin e6, a photosensitizer. Moreover, fluo-
rescence is also emitted by the irradiated photosensitizer, 
allowing its detection and tracking in in vitro and in vivo 
investigations.[172] The cellular uptake of chlorin e6-loaded 
hydrophobically modified and unmodified FITC@GChNPs 
was assessed in squamous cell carcinoma cell line (SCC-7) 
which showed FITC green stains in the cytoplasm, sug-
gesting efficient incorporation of both types of NPs. How-
ever, stronger fluorescence was detected for chlorin e6-loaded, 
hydrophobically modified FITC@GChNPs with the release of 
cargo occurring within 1 h. This result indicated a fast cellular 
uptake of NPs occurring through several endocytic pathways 
such as macropynocytosis,[173] and classified hydrophobically 
modified FITC@GChNPs as an efficient vehicle for photody-
namic therapy.[169]
Figure 9. Representation of the MSC organization and distribution of 
FITC@CMChNP carrying Dox.
Figure 10. Permeability of FITC@ChNPs through the cell monolayer.
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The photosensitizer pheophorbide a (Ppa) was encapsulated 
in glycol chitosan NPs through a bioreducible disulfide linkage 
(Ppa-ds-GCh).[174] The resulting NPs were shown to possess 
switchable photoactivity and efficient release of Ppa, owing to a 
quicker enzyme-induced dissociation.[174] NPs with no disulfide 
linker were taken as control (Ppa-GCh). The cellular uptake of 
NPs was performed in KB cells by labeling chitosan with FITC. 
Cells were incubated with the fluorescent NPs (Ppa-ds-GCh 
and Ppa-GCh) for 1, 4, and 8 h and then analyzed by CLSM. 
Images showed that green spots appeared in the cytoplasm as 
soon as after 1 h incubation. After 4 h incubation, green and red 
spots (due to Ppa fluorescence) appeared in the cytoplasm of 
cells treated with Ppa-ds-GCh NPs. Instead, cells treated with 
the control presented few red spots. This result indicated that 
Ppa was released in the cytosol more quickly when it was incor-
porated in Ppa-ds-GCh NPs than Ppa-GCh NPs, inducing an 
anticancer specific effect.[174]
Wu and Zhao[167] used polyethylene-glycol-modified single-
walled carbon nanotubes (SWCNTs) for the transport of a pho-
tosensitizer, pyropheophorbide a (Pppa), to the target site.[175] 
To increase the targeting ability of SWCNTs, their surface was 
modified with chitosan, which provided increased water solu-
bility of the SWCNTs and allowed the binding of FA, a tumor-
homing molecule. Moreover, chitosan was conjugated with 
FITC to allow SWCNTs visualization in cellular uptake studies, 
employing HeLa cells known to overexpress the FA-R on their 
surface.[149] Treatment of HeLa cells with the FA-modified Ch-
SWCNTs induced a strong intracellular green signal which was 
absent in control cells treated with free FITC. To assess the tar-
geting ability of FA-modified Ch-SWCNTs, experiments at 4 °C 
and in the presence of free FA were conducted. In both cases, 
the fluorescence intensity decreased, indicating that the low 
temperature and the free FA reduced the effectiveness of Fa-
modified Ch-SWCNTs. This experiment confirmed that FA-R-
mediated endocytosis was active. Furthermore, the conjugation 
of Pppa-loaded, FA-modified Ch-SWCNTs with FITC allowed 
the performance of “fluorescence imaging-guided cancer 
PDT.”[167] Indeed, upon irradiation, the photosensitizer emitted 
a red fluorescence that overlapped with the green fluorescence 
given by the NC, suggesting that the cargo was effectively deliv-
ered inside the cells.[167]
5.2. Hypoxia Therapy
Hypoxia is a very common pathological condition occurring in 
several diseases such as cancer and ischemia, characterized by 
a reduced concentration of oxygen in tissues.[176]
FITC@ChNPs were applied for the delivery of antioxidants 
such as Trolox for the treatment of disease related to hypoxia-
mediated oxidative stress.[177] In this study, the stability of 
ChNPs was improved by modifying chitosan structure with 
hydroxylethyl groups, showed to increase water solubility of 
polymers.[178] The intracellular tracking of fluorescent NPs 
was investigated in P12 cells, which were also stained for lys-
osomes by LysoTracker Red. After 12 h incubation, NPs were 
observed within the cytoplasm, indicating that they could suc-
cessfully permeate through the cellular membrane of cells 
by endocytosis. Images taken after 6 h showed that the green 
fluorescence belonging to FITC and the red fluorescence 
given by LysoTracker were overlapped, suggesting that a lyso-
somal pathway was undertaken by NPs which degraded in the 
acidic environment releasing their cargo in the cytoplasm.[177] 
Further, to define the endocytosis uptake pathway, cells were 
treated with a caveolae inhibitor, and a significant decrease in 
the number of stained cells was recorded. The authors[177] con-
cluded that ChNPs were engulfed by cells through a caveolin-
mediated transport and that the release of Trolox in the lys-
osomes played a key role in the protection of cellular apoptosis.
In the case of cancer, hypoxia leads tumors to produce 
angiogenic factors so that a high density of blood vessels is 
produced.[179] However, the newly formed blood vessels do not 
always meet the needs of the growing tumor, so they appeared 
damaged, with an inadequate structure.[180] Indeed, they are 
characterized by a leaky structure which leads NCs to accu-
mulate passively in tumors, a phenomenon known as EPR 
effect. For instance, glycol ChNPs have been found to show 
this effect.[41] Jang et  al.[181] generated hypoxia-responsive NPs 
by conjugating glycol chitosan to a hydrophobic core made of 
4-nitrobenzyl chloroformate (4-Nc) by a bond which, in hypoxic 
conditions, is cleaved by nitroreductase and NADPH, so the 
cargo is released.[182] To further increase the target tumor effect, 
FA was also conjugated in the chitosan structure and Dox was 
loaded in the hydrophobic core. In vitro cellular uptake studies 
were carried out on FA-R-positive A549 cells and FA-R-negative 
MCF7 cells. To allow visualization of NPs, chitosan was con-
jugated to FITC to obtain FA-modified FITC@GCh/4NcNPs. 
Following incubation of cells with fluorescent NPs, the fluo-
rescence intensity was detected using an inverted fluorescence 
microscope. Images showed that NPs were taken up more effi-
ciently by A549 cells, compared to MCF7 cells, confirming the 
ability of FA to target cells that express its receptor. The intra-
cellular delivery of Dox (red) was evaluated in hypoxic condi-
tions, which were induced in an incubator set at 37 °C, 1% O2, 
5% CO2. In these conditions, a higher release of Dox (80%) was 
observed, compared to normal incubation conditions (25%), 
suggesting that FA-modified GCh/4NcNPs can selectively 
deliver drugs to hypoxic cells.
5.3. Gene Therapy
Considerable attention has been paid to nucleic acid delivery 
through NCs for biomedical applications.[183] Naked DNA and 
RNA are characterized by high susceptibility to nuclease degra-
dation, poor cellular uptake, and low transfection efficiency,[184] 
and to overcome these issues, an effective carrier is needed.[184] 
Viral vectors such as retrovirus and adenoviruses have been 
widely used for this purpose.[185] However, the use of viral vec-
tors may be unsafe in humans, since they have been associated 
with inflammation, cancer, or even death.[186,187] Thus, no viral 
vector has been approved by the FDA.[188]
Nonviral vectors have attracted increasing attention due to 
their safety, low immunogenicity, and high gene loading.[189] 
Chitosan is a promising candidate as a nonviral vector for gene 
therapy of many acquired or innate diseases.[190] In fact, the 
protonated amino groups on chitosan can establish nanosized 
complexes (polyplexes) based on ionic interactions with the 
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negatively charged plasmid DNA (pDNA) or small interfering 
RNAs (siRNA).[188,191]
5.3.1. Plasmid DNA
Chitosan needs some modifications of its structure to allow 
targeted gene delivery to tumors. For instance, to increase 
the targeted delivery of nonviral vectors based on chitosan to 
hepatocytes, Hashimoto et  al.[183] employed the receptor-medi-
ated gene delivery strategy: taking advantage of sugar receptors 
on hepatocytes such as asialoglycoprotein receptors,[192] pDNA 
(labeled with YOYO-1) complexes were formed using lacto-
sylated chitosan (L-Ch) with 8% of lactose residues, labeled with 
FITC. Cellular uptake studies of FITC@L-Ch/pDNA complexes 
were performed on HepG2 and renal fibroblasts cell line (COS7 
cells), used as control as asialoglycoprotein receptor-negative. 
The trypan blue technique was used to assess the number of 
FITC@L-Ch/pDNA complexes engulfed by the cells. Although 
no significant difference was found between cell lines, the 
transfection efficiency was significantly higher for HepG2 than 
COS7 cells, owing to the asialoglycoprotein receptors on hepat-
ocytes. Further, the subcellular localization of FITC@L-Ch/
pDNA complexes was detected in HepG2 cells by CLSM. The 
complexes appeared on the cell surfaces after 5 min incubation 
and around the nucleus after 15  min. The use of endocytosis 
inhibitors showed that the high gene expression of L-Ch/pDNA 
complexes was given by their release from the early endosomes 
and transport into the nucleus.[183]
However, the gene transfection efficiency of chitosan is very 
low for clinical use, owing to the strong electrostatic interactions 
between the positively charged chitosan and negatively charged 
DNA, preventing its release inside the nucleus.[193] Chemical 
modifications using peptides present in the chitosan structure 
can help to overcome this limitation. Peng et  al.[194] employed 
the peptide, poly(γ-glutamic acid), (γ-PGA), to modify the struc-
ture of Ch/pDNA complexes, with the aim of enhancing the 
release of the DNA at the site of action. To quantify their uptake 
by human fibrosarcoma HT1080 cells, NPs were labeled with 
FITC and flow cytometry analysis was performed. The fluores-
cence intensity of cells engulfing fluorescence NPs increased 
with the amount of γ-PGA incorporated in the chitosan. Cells 
were also treated with increasing concentrations of trypsin 
before incubation with NPs, to assess any interaction of NPs 
with cell-surface proteins. This assay significantly decreased the 
internalization of fluorescent NPs, regardless of the presence of 
γ-PGA. However, the concentration depending effect was more 
pronounced in Ch/γ-PGA/pDNA NPs compared to Ch/pDNA 
NPs. Altogether these results suggested that a specific protein-
mediated endocytosis increase the uptake of NPs modified with 
γ-PGA.
In a further investigation, Peng et  al.[128] assessed the cel-
lular uptake of FITC@Ch/γ-PGA/pDNA NPs by treating 
HT1080 cells with inhibitors of cellular uptake pathways, such 
as chlorpromazine that inhibits the CME.[195] Following treat-
ment with the inhibitors, cells were transfected with NPs and 
then analyzed by flow cytometry. Treatment with chlorproma-
zine increased the cellular uptake of both, FITC@Ch/γ-PGA/
pDNA NPs and FITC@Ch/pDNA NPs (control). This result 
indicated that CME was not involved in the uptake of NPs, 
while other pathways were upregulated in the presence of 
chlorpromazine.[128] Treatment with micropinocytosis inhibi-
tors, wortmannin and cytochalasin D, induced the cellular 
uptake of FITC@Ch/pDNA NPs to decrease by 3%, suggesting 
that a minor number of FITC@Ch/pDNA NPs followed this 
pathway. Instead, greater inhibition of the uptake was recorded 
for FITC@Ch/γ-PGA/pDNA NPs (20–30%) suggesting that 
micropinocytosis played a key role in the cellular uptake of the 
examined NPs. Finally, cells were treated with two inhibitors of 
the caveolae-mediated pathway: filipin, blocking caveolae invag-
ination, and genistein, blocking the lipid-raft-mediated endo-
cytosis.[195] Interestingly, in the case of treatment with filipin, 
the cellular uptakes of both types of NPs (FITC@Ch/γ-PGA/
pDNA NPs and FITC@Ch/pDNA NPs) increased, whereas 
genistein inhibited the uptake by 55% for the control and 90% 
for Ch/γ-PGA/pDNA NPs. These results suggest that the cave-
olae-mediated pathway was predominant in the internalization 
of NPs and was related more to lipid-raft-mediated endocytosis 
than invagination of caveolae.[128]
Li et  al.[196] generated DNA-loaded FITC@ChNPs, modified 
with the peptide, glutathione (GSH), which can form disulfide 
bonds to the mucin glycoproteins of cell membranes.[197,198] 
PEG was also introduced to decrease plasma protein adsorp-
tion, increasing NPs circulation time in the blood.[199] To esti-
mate the transfection efficiency of those NPs in the presence 
or absence of GSH, their interaction with cell membranes 
was investigated in a murine embryonic fibroblast cell line 
(NIH3T3) by flow cytometry. Results showed that the fluores-
cence efficiency of GSH-modified NPs was significantly higher 
than unmodified NPs, suggesting a higher cellular uptake for 
GSH-modified NPs.[196] The same research group expanded the 
investigations on DNA-loaded FITC@ChNPs modified with 
GSH and PEG toward the cellular uptake of HeLa and HepG2 
cells.[200] Analysis of fluorescence intensity revealed that the 
highest value was achieved for HepG2 cells owing to stronger 
binding of GSH-modified NPs to these cells. The authors[200] 
concluded that GSH- and PEG-modified ChNPs could be an 
efficient gene delivery system, especially for liver cancer.
Since the poor solubility of chitosan in physiological condi-
tions limits its gene transfection efficiency,[201] Yoo et  al.[202] 
employed self-assembled polymeric amphiphiles composed 
of FITC@glycol chitosan hydrophobically modified with 
5β-cholanic acid, interacting with hydrophobized pDNA 
(obtained by reaction with cethyltrimethylammonium bro-
mide). Cellular uptake studies were carried out in fibroblast-
like COS-1 cells and analyzed by CLSM. Images showed that 
the NPs were successfully engulfed by the cells because the 
positive charge of glycol chitosan enhanced the transfection 
efficiency.[202]
Toh et  al.[203] employed a low MW chitosan (with improved 
water solubility) in which carboxyl groups and succinic anhy-
dride were introduced to obtain succinated chitosan (Ch-succ), 
forming NPs by self-assembly.[204] Ch-succ was labeled with 
FITC to perform cellular uptake studies in a human kidney 
cell line (293T cells). Polyplexes were formed by adding pDNA 
labeled with EtBr (red) to FITC@Ch-succ and to FITC@Ch, as 
a control. After 6 h incubation with the polyplexes, cells were 
analyzed by CLSM. In physiological media, the DNA was seen 
Macromol. Biosci. 2021, 21, 2000312
2000312 (17 of 27)
www.advancedsciencenews.com www.mbs-journal.de
© 2020 The Authors. Published by Wiley-VCH GmbH
to be well-encapsulated in the chitosan structure, forming a 
stable polyplex colored green with a touch of yellow. The sta-
bility of polyplexes was found to be vital for efficient intracel-
lular delivery of pDNA.[205] Moreover, the polyplexes were 
observed in the perinuclear region with a more intense red 
fluorescence for polyplexes composed of Ch-succ than for the 
control. However, the high degree of substitution of Ch-succ 
was found to be a determinant for both the water solubility of 
Ch-succ and its ability to retain the DNA, and hence for the 
transfection efficiency of the carrier.[203]
Jiang et  al.[206] generated a gene delivery system for ocular 
gene transfection formed by cationic core–shell liposome-NPs, 
based on ChNPs enveloping pDNA and a lipid shell. This 
system was shown to protect pDNA from nuclease disintegra-
tion, facilitate the cellular uptake, avoid endolysosomes, and 
transfer the pDNA directly to the nucleus.[207,208] The cellular 
uptake was assessed in vitro employing human conjunctival 
epithelial cells and conjugating chitosan to FITC, to obtain 
FITC@Ch/pDNA lipoNPs. Cells were treated with the NPs, 
washed, and lysed to assess the fluorescence intensity. FITC@
Ch/pDNA lipoNPs were taken up more efficiently by cells than 
the controls (ChNPs, lipid micelles). CLSM images were taken 
to assess the location of NPs whose green signal was detected 
intracellularly and was higher than the control, confirming 
the previous results. Experiments performed at 4  °C showed 
significantly reduced cellular uptake, indicating that the endo-
cytic pathway was energy dependent. Treatment with filipin 
(a specific inhibitor of caveola pathway), CPZ (an inhibitor of 
clathrin pathway), and CyD (an inhibitor of polymerization and 
membrane ruffling processes) was performed. CLSM images 
showed that the three inhibitors reduced the cellular uptake, 
indicating that the three pathways were involved the cellular 
uptake of FITC@Ch/pDNA lipoNPs to some extent. Further, 
LysoTracker Red was used to stain the lysosomes, and following 
1 h treatment with FITC@Ch/pDNA lipoNPs, yellow fluores-
cence (green overlapped with red) was seen intracellularly. After 
2 h treatment, the green fluorescence of FITC@Ch/pDNA 
lipoNPs was detected in the cytoplasm, while no signal was 
detected in cells treated with ChNPs, indicating that the cati-
onic system was able to escape the endosomes.[206]
Layek and Singh[209] assessed the performance of polyplexes, 
composed of pDNA and hydrophobically modified chitosan, in 
increasing gene transfection. Chitosan was modified with four 
hydrophobic amino acids including L-(alanine, valine, leucine, 
and isoleucine) and then labeled with FITC, for cellular uptake 
studies, on human embryonic kidney cells (HEK 293). Confocal 
images showed that polyplexes were efficiently internalized into 
cells upon 4 h incubation. Interestingly, the number of fluores-
cent cells and the fluorescence intensity were positively corre-
lated with the hydrophobicity of the peptide on the structure of 
chitosan.[209] This result suggested that the process of endocy-
tosis was facilitated by the co-presence of positive charges and 
hydrophobic moieties on chitosan structure.[210]
To increase the gene delivery efficiency of Ch-based gene 
NCs, Layek et al.[188] modified chitosan structure with a proper 
combination of hexanoic acid (Ha), as a hydrophobic moiety,[211] 
and monomethoxy poly(ethylene glycol) (mPEG), due to its 
properties such as high water solubility and nontoxicity.[212] 
Modified chitosan was also labeled with FITC before generating 
micelles/polyplexes with pDNA, so to evaluate the uptake of 
HEK 293 cells. After incubating cells with the fluorescent poly-
plexes, cells were harvested, and the FITC-positive cells were 
quantified by flow cytometry. Treatment with Ha and mPEG-
modified Ch polyplexes increased the number of FITC-positive 
cells by 4.5 times, compared to unmodified Ch polyplexes. 
The mechanisms of cellular uptake were investigated by using 
endocytosis pathway inhibitors such as sodium azide, which 
inhibits all transport involving energy and chlorpromazine, 
which inhibits clathrin-mediated endocytosis.[213] Flow cytom-
etry results showed that sodium azide decreased the number 
of FITC@positive cells by 82%, and that chlorpromazine 
decreased the uptake by 61.4%; hence clathrin-mediated endo-
cytosis was considered the main pathway in the uptake of Ha 
and mPEG-modified Ch polyplexes by kidney cells.
The potential of ChNPs to act as a nonviral delivery system 
in mucosal vaccination was assessed by Lebre et al.[214] Human 
serum albumin (hSA) was absorbed on the surface of ChNPs, 
to increase the transfection efficiency of DNA-loaded ChNPs 
by reducing the interaction between DNA and chitosan.[215,216] 
Chitosan was also labeled with FITC (green) and NPs were 
loaded with plasmid DNA labeled with Cy-5 (red) to obtain 
Cy-5@DNA-loaded FITC@hSA/ChNPs.[214] Cell uptake studies 
in A549 cells were then performed. Confocal images revealed a 
yellow fluorescence, due to overlapping FITC@Ch and Cy-5@
DNA, in the cytoplasm of the cells after 4 h incubation with 
NPs. Moreover, after 8 h, Cy-5@DNA was detected in the 
nucleus, suggesting that hAS/ChNPs were able to deliver DNA 
efficiently to the nucleus for transcription to take place.[214]
5.3.2. Small Interfering RNA
Farid et  al.[217] explored the possibility for FITC@ChNPs to 
act as carrier of siRNA directed toward the scavenger receptor 
class B type 1 (SRB1). This receptor is expressed in the liver, 
involved in the regulation of lipid metabolism, and in the 
pathogenesis of hepatitis C.[218] Hence, its silencing would be 
beneficial to prevent virus C entrance.[219] The physico-chemical 
properties of NPs were adjusted using the ionic gelation tech-
nique to obtain a particle size of ≈77 nm and a surface charge 
of ≈+45 mV. Loading with siRNA slightly increased the particle 
size and decreased the surface charge to +34 mV, due to partial 
neutralization of the chitosan’s positive charges by interaction 
with the negatively charged siRNA. The uptake of SRB1 siRNA-
loaded FITC@ChNPs was assessed in HepG2 cells. Measure-
ment of the fluorescence intensity affirmed that NPs were 
efficiently taken up by cells and the cellular internalization was 
both on incubation time and NPs concentration.
An siRNA directed toward the P-glycoprotein, overcoming 
multi-drug resistance in cancer, was successfully encapsu-
lated in tumor homing thiolated glycol chitosan NPs.[220] A 
self-polymerized 5′-end thiol-modified siRNA (poly-siRNA) 
was employed to obtain stable and condensed NPs.[220] Adria-
mycin-resistant variant human breast cancer MCF-7/ADR cells 
were employed to assess the cellular uptake of FITC@NPs. 
Cells treated with free poly-siRNA (red) were taken as control. 
Images showed no intracellular red spots in the control, indi-
cating that the poly-siRNA was not able to cross the cellular 
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membrane on its own. In contrast, both green and red spots 
appeared in the cytoplasm of cells treated with poly-siRNA 
loaded NPs, implying that they could facilitate the delivery of 
siRNA to the drug-resistance cancer cell line.[220]
Wang et al.[221] applied the properties of FITC@ChNPs in the 
context of stem-cell therapy, efficient in tissue regeneration.[222] 
To overcome the low efficiency of cell suspension injection, cell 
sheet engineering is now being used to deliver seeding stem 
cells with a preserved extracellular matrix around them.[60] 
Moreover, it is aimed to deliver therapeutic agents such as 
small interfering (si) RNA or micro (m) RNA to stem cells for 
enhanced therapeutic outcomes.[223] In this context, chitosan 
and hyaluronic acid (Ha) NPs can act as vectors to protect 
mRNA and efficiently target its delivery inside the cells. The 
presence of Ha caused ChNPs to be stable in the blood, have 
narrow size distribution, and the ability to bind to CD44, a cel-
lular receptor expressed by many cells such as healthy human 
bone marrow mesenchymal stem cells (hBMMSCs).[224] Polye-
lectrolyte complexation was employed to form Ch/Ha NPs, and 
mRNA was loaded via electrostatic interaction.[221] The resulting 
NPs were coated onto culture plates where cell sheets com-
posed of hBMMSCs were induced by the vitamin C method.[225] 
To assess the effective absorption of mRNA in the NPs and 
the distribution of NPs on the plate, chitosan was labeled with 
FITC while the mRNA was labeled with Cy-3. Images of the 
fluorescence microscopy showed an even distribution of NPs 
and mRNA on the culture plate. Overlapping imaging dem-
onstrated that the mRNA was well retained by the NPs after 
the coating. Their internalization of FITC@Ch/HaNPs was 
monitored in hBMMSCs by fluorescence microscopy. Images 
showed that mRNA-loaded NPs were concentrated in the body 
of cells, especially in the perinuclear region. Yet, overlapped 
images showed that Cy-3-labeled mRNA was well retained in 
the FITC@Ch/HaNPs.[221]
Since the ionic interaction between the positively charged 
glycol chitosan and the negatively charged siRNA poses limita-
tions in forming a condensed and stable complex, Huh et al.[226] 
developed a gene carrier system based on self-assembled 
FITC@glycol chitosan and polyethylenimine (Pei) NPs. The 
use of Pei allowed the introduction of strong positive charges 
that tightly condensed the siRNA complex, while glycol chi-
tosan ensured tumor targeting properties.[34] Cellular uptake 
studies were performed on B16F10 cells and analyzed by CLSM. 
Since the siRNA was labeled with Cy5.5 (red), the localization 
of FITC@NPs in cells appeared in yellow. Cy5.5@siRNA was 
taken as control. The cellular uptake was found to be time-
dependent: NPs appeared attached to the cell membrane after 
2 min of incubation while the yellow dots appeared in the cyto-
plasm in the following 30  min. In contrast, the control (red 
spot) appeared on the cell membrane for the entire incubation 
time, suggesting that Cy5.5@siRNA-loaded FITC@glycol Ch/
Pei were able to penetrate the cell membrane and transport the 
siRNA in the cytoplasm. Finally, after 1 incubation, red spots 
appeared in the cytoplasm, indicating that NPs escaped the lys-
osomes releasing the siRNA in the cytoplasm.[226]
Lee et  al.[227] synthesized a polymeric siRNA nanostruc-
ture, using a technique known as rolling circle transcription, 
for tumor-targeted gene delivery. The resulting siRNA was 
then complexed to thiol-modified glycol chitosan (tgCh), as a 
delivery carrier characterized by tumor-homing properties.[34] 
To assess the intracellular delivery efficiency of FITC@siRNA/
tgCh NPs in human prostate tumor cells (PC3), the polymer 
tgCh was conjugated to FITC while siRNA was labeled to Cy-3. 
Confocal images showed a higher fluorescence intensity related 
to FITC and Cy-3 in the cytoplasm than free siRNA, suggesting 
an efficient uptake of NPs.[227] A previous study found that the 
enhanced transfection of siRNA/tgCh NPs occurred by several 
pathways such as clathrin- and caveolae-mediated endocytosis 
and micropinocytosis.[213]
Chitosan lactate was shown to possess higher water solu-
bility properties and gene transfection efficiency than pristine 
chitosan.[228] In a recent study, FITC@Ch lactate was employed 
to prepare NPs encapsulating siRNA for the treatment of dia-
betes.[229] The siRNA employed in this study was targeted to 
the liver, to decrease the expression of genes involved in the 
gluconeogenesis, which plays a key role in promoting dia-
betes.[230] Therefore, to increase the targeting efficiency of 
siRNA-loaded NPs, Ga was used as an efficient targeting ligand 
of Ga receptors on liver cells, as discussed in Section 2.3.2. Ga 
was conjugated to a PEG coat that increased the in vivo sta-
bility of Ch lactate NPs.[229] Cellular uptake studies were per-
formed on HepG2 cells. The visualization of NPs was due to 
FITC labeling of chitosan while siRNA was labeled with Cy-3. 
PEG/Ga-uncoated Cy-3@siRNA-loaded FITC@ChNPs were 
taken as control. Confocal images detected a stronger orange 
fluorescence in cells treated with PEG/Ga-coated Cy-3@si-
RNA-loaded FITC@Ch lactate NPs, compared to the control. 
This result was confirmed by quantitative analysis performed 
by flow cytometry, showing that the uptake of PEG/Ga-coated 
NPs was twofold higher than the control. Further, in vivo bio-
distribution studies were performed on male Wistar rats. The 
animals were sacrificed after 2 h treatment with the fluores-
cent NPs and the major organs along with blood were col-
lected. Samples were homogenized and centrifuged, and the 
supernatants were analyzed by fluorescence microscopy. Inter-
estingly, a higher fluorescence intensity was recorded in RES 
organs and liver for animals treated with the control, whereas 
for animals treated with PEG/Ga-coated NPs, a high fluores-
cence intensity was recorded in the liver. Therefore, PEG/Ga-
coated si-RNA-loaded NPs is a promising candidate for inhib-
iting the gluconeogenesis in diabetes.[229]
5.4. Fungal Uptake Studies
Fungal infection diseases can cause serious morbidity and even 
mortality in immunodeficiency cases, along with relevant dis-
eases in plants, threatening the safety of agriculture products. 
FITC@ChNPs have seen their application in the treatment of 
fungal infectious disease.
Owing to the well-known antimicrobial properties of chi-
tosan, the antifungal effect of oleoyl-chitosan (Ol-Ch) NPs was 
assessed on Verticillium dahlia (V. dahlia), the major cause of 
infection in plants.[231] The cellular uptake by V. dahlia mycelia 
was assessed by labeling chitosan to FITC. Fungal spores were 
incubated with FITC@OlChNPs. The location of fluorescent 
NPs was observed by fluorescence microscopy, which showed 
green spots due to FITC@OlCh NPs localized in the spores, 
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suggesting that NPs could permeate the fungal membrane and 
exert an antifungal activity.[231]
Amphotericin B (AmpB) is used to treat several mycoses, 
despite severe toxicity to healthy tissues.[232] It has been shown 
that when AmpB is encapsulated in polymeric micelles, its 
toxicity is reduced.[232] Linolenic acid (La) was shown to have 
antifungal activity by targeting the fungal cell membrane.[233] 
Moreover, chitosan hemolysis was found to be reduced by con-
jugation with methoxy poly (ethylene glycol) (mPEG).[234] Song 
et  al.[235] assessed the ability of La-modified mPEG oligochi-
tosan conjugate micelles, encapsulating AmpB, to increase 
the fungal cellular uptake. Candida albicans was employed to 
assess the cellular uptake of FITC-labeled conjugates, using 
FITC@mPEG NPs and FITC@mPEGCh NPs as controls. 
Fluorescence-inverted microscopy analysis detected a very 
weak signal in the presence of FITC@mPEG NPs while the 
signal was stronger after incubation with FITC@mPEGCh 
NPs, owing to the electrostatic interaction of chitosan with the 
fungal membrane. However, the fluorescence intensity became 
even stronger following incubation with La-modified FITC@
mPEGCh NPs, owing to the ability of La to interact with the 
fungal membrane.[233] La-modified FITC@mPEGCh NPs 
showed a combined ability to interact with fungal membrane, 
increasing the delivery of AmpB.[235]
6. Cellular Labeling
Magnetic FITC@ChNPs are extensively used for biomedical 
in vivo applications, including in vivo disorders diagnosis 
or in situ control of living cells, e.g., transplanted cells, since 
they can be easily monitored by magnetic resonance imaging 
(MRI) and fluorescent microscopy.[236] Cytotoxic studies proved 
the biocompatibility for biomedical in vivo studies of magnetic 
FITC@ChNPs.[237,238]
An effective detection method of monitoring the location of 
labeled cells in the body was investigated by Ge et al.[237] The fea-
sibility of magnetic FITC@ChNPs to efficiently label the human 
hepatoma SMMC-7721 cell line was assessed, at increasing dose 
of NPs and incubation times. Flow cytometry data showed that 
almost 90% of cells were labeled at a very low concentration of 
FITC@NPs (15.44 µg) after a very short incubation time (30 min). 
This proved the high cellular affinity for FITC@ChNPs. Further-
more, fluorescence and electron microscopy studies revealed that 
fluorescent NPs were located both inside the cells (especially in 
lysosomes or late endosomes) and on their surface. These data 
indicated that fluorescent magnetic NPs could be a valuable tool 
for direct imaging of cells in living tissues.
In a study performed by Chekina et al.,[238] rat mesenchymal 
stem cells (rMSCs) were used as a model for cellular labeling 
efficiency, then translated in vivo studies. Magnetic FITC@
NPs were coated with carboxymethyl chitosan (CMCh) to pro-
mote cell uptake and with inert silica to prevent quenching of 
the fluorochrome by the iron oxide. Uncoated NPs were used 
for comparison. Cells were isolated, passaged, and labeled 
with fluorescent NPs. Cellular labeling efficiency was assessed 
by counting Prussian Blue-stained cells and it was found that 
CMCh and silica-coated NPs provided a higher labeling effi-
ciency (64%) than the uncoated NPs (48%). This suggests that 
both CMCh and silica were needed to allow the visualization of 
cells. FITC@rMSC were then injected into rat brains, and the 
cellular movement and migration were monitored by in vivo 
MRI. Altogether, these results indicated that FITC@NPs coated 
with silica or CMCh are a valuable tool to investigate the inter-
actions of NPs both in in vitro cell culture and in vivo.[238]
Following studies aimed to label rMSCs using magnetic 
FITC@ChNPs, generated by Kaewsaneha et  al.[239,240] After 
incubation of rMSC with NPs, the labeling efficiency was time-
dependent, achieving the highest fluorescence after 24 h incu-
bation with no impacts on cell viability. Labeled cells were then 
3D imaged to check the location of NPs which were mainly 
detected in the cytoplasm, suggesting endocytosis as the uptake 
mechanism. These results classify magnetic FITC@ChNPs as a 
powerful potential tool for rMSC labeling, allowing cell tracking 
and visualization by fluorimetry.[239]
Kaewsaneha et  al.[241] used a method developed by Kaews-
aneha et  al.,[240] incorporating iron oxide into polystyrene/
divinyl benzene/acrylic acid by miniemulsion polymerization 
while FITC was immobilized using chitosan as a spacer. The 
MW of chitosan employed in this method was high enough 
(300  kDa) to avoid direct contact between the iron core and 
FITC, so that quenching was prevented. The resulting NPs 
were used to detect both solid organ and blood cancer cells such 
as HeLa, Hep G2, and K562 cells (a human leukemic cell line). 
Confocal images showed that NPs were successfully engulfed 
by all types of cells within 3 h of incubation with no impact 
on cell viability. However, K562 cells provided the shortest time 
to maximum fluorescence intensity, possibly due to the floated 
nature of these cells allowing a larger number of NPs to attach 
to, and penetrate, their surface in a short time. The fluorescent 
NPs were localized in the cytoplasm and cell membrane, hence 
classified as an efficient tool in cell labeling.
The plasma membrane plays a key role in protecting the cell 
from the outside, along with being essential in many biolog-
ical processes such as cell adhesion, migration, proliferation, 
endocytosis, exocytosis, and apoptosis.[242] Imaging of the cell 
membrane is key in the pursuit of biological investigations or 
cell surface engineering, but the use of fluorescent dyes that 
specifically label the plasma membrane is challenging; hence 
several methodologies have been explored.[243] Wang et  al.[242] 
developed an efficient, simple, and low-cost plasma mem-
brane tracker, based on FITC@glycol chitosan (as a highly 
water-soluble backbone) and PEG/cholesterols (as hydrophobic 
anchoring moieties). These moieties are expected to bind to 
the basolateral side of the lipid bilayer, and visualization of the 
membrane is possible owing to the fluorescence emitted by 
FITC. The resulting molecules had a mean size of 20 nm and a 
very narrow size distribution. To ensure an efficient application, 
the cytotoxicity of fluorescent NPs was evaluated in HepG2 
cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. No cytotoxicity was recorded even at 
high doses. CLSM images showed that the cell membrane of 
all cell types under investigation was successfully stained using 
FITC@glycol chitosan and PEG/cholesterols. These cell types 
included the normal lung alveolar type II, and the following 
tumorigenic cell types: KB, A549, MDA-MB-231, and HepG2 
cells, suggesting that it can be used to stain the plasma mem-
brane of both healthy and cancerous cells.[242]
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7. Oral Drug Bioavailability
The oral administration of drugs is more convenient and 
acceptable than conventional i.v. administration, which shows 
several drawbacks such as pain, infections, and poor patient 
compliance.[244] However, to be effective a drug must be avail-
able in the bloodstream, hence orally administered drugs must 
be able to overcome GI barriers,[245] represented by the GI pH 
and GI enzymes responsible for protein drugs degradation.[246] 
Moreover, the GI epithelium prevents the paracellular transport 
of any drugs, owing to the presence of TJs, and there is a large 
transcellular diffusion barrier for hydrophilic drugs owing to 
the hydrophobic bilayer.[247] To improve the oral bioavailability 
of drugs, intestinal permeation enhancers such as chitosan and 
its derivatives have been investigated in the literature.[248] In 
fact, chitosan’s properties play a key role by establishing elec-
trostatic interactions with the negatively charged sialic acid resi-
dues on the mucin glycoproteins of GI epithelial cells, causing 
the NCs adhesion and in turn, releasing the drug into the 
bloodstream.[249] In this context, FITC helps in the visualiza-
tion of ChNC’s transport across the GI epithelium, establishing 
the suitability of ChNCs for oral drug. This is a noninvasive 
method, safely applied in Caco-2 cells investigations with no 
modification on their cellular structure.[250] Caco-2 cells cul-
tured on permeable filter supports are considered the golden 
standard for in vitro assays that predict GI drug permeability 
and absorption.[251]
7.1. Chitosan-Based NCs of Model Peptide Drugs
Insulin is the main protein hormone produced by β cells located 
in the pancreatic islet of Langerhans. It is used to manage dia-
betes and administered through subcutaneous injection which 
is the main cause of poor patient compliance. Therefore, orally 
administered insulin would be the most preferable route for 
patients.[252] Several strategies employing FITC@Ch NCs have 
been explored to increase the transport of insulin through the 
GI epithelium.
An early study conducted by Lin et  al.[253] focused on the 
oral delivery of insulin through NPs based on low MW chi-
tosan and poly(γ-glutamic acid) (γ-pGA) which is a natural 
anionic peptide.[254] Chitosan was stained with FITC for CLSM 
studies so as to obtain FITC@Ch/γ-pGANPs. The transport of 
those NPs was explored in Caco-2 cells at different pH values 
(6.6 and 7.4), mimicking the pH of the intestinal tract. After 
incubation of Caco-2 cells with FITC@Ch/γ-pGANPs for 1 h, a 
strong green fluorescence given by FITC was detected between 
cells at pH 6.6, indicating that NPs could mediate the paracel-
lular transport between Caco-2 cells. However, no signal was 
detected at pH 7.4, suggesting that NPs disintegrated at this 
pH. Staining of TJs confirmed these results: following treat-
ment with NPs at pH 6.6, they appeared discontinuous, sug-
gesting their opening, while appearing continuous again upon 
NPs removal.[253,255] Furthermore, in vivo studies in induced-
diabetic Wistar rats showed that the blood glucose level 
decreased significantly upon oral administration of insulin-
loaded Ch/ γ-pGA NPs comparing to insulin solution, in a 
dose-dependent manner.[253]
The oral delivery of insulin was investigated by Makhlof 
et  al.[256] using FITC@ChNPs crosslinked with a pH-sensitive 
polymer, methylcellulose phthalate (HPMCP) to protect NPs 
from gastric degradation. FITC@ChNPs formulated by ionic 
gelation were taken as control. FITC@NPs were assessed for 
in vivo intestinal mucoadhesion studies, in male Wistar rats by 
CLSM. The animals were sacrificed 1 or 3 h after oral admin-
istration of insulin-loaded FITC@ChNPs. Stomach and small 
intestinal regions were extracted, opened longitudinally, and 
digested with sodium hydroxide solution. Samples were centri-
fuged and the supernatant was analyzed by fluorophotometry. 
Untreated animals were taken as control. A higher fluorescent 
intensity was noticed in the ileal fractions compared to stomach 
and duodenal tissue. This was probably due to different thick-
nesses of the mucous gel layer (the ileum has a significantly 
thicker mucous layer than other regions of the intestine) and 
different travelling times in each intestinal section (being faster 
in the duodenum and decreasing in the terminal ileum). The 
mucoadhesive properties of FITC@ChNPs formulated with 
or without HPMCP were also evaluated: a higher fluorescence 
was observed when NPs were formulated with HPMCP in 
the GI mucosal tissue, owing to HPMCP’s ability to preserve 
ChNPs from gastric digestion. Furthermore, CLSM images of 
cross-sections of the intestinal membrane were taken to deter-
mine the position of NPs within the tissue and found that NPs 
interacted with the intestinal membrane rather than just being 
entrapped in the mucous gel layer.[256]
Sonaje et al.[257] investigated the ability of chitosan modified 
with poly(γ-glutamic acid) (γ-PGA) NPs,[258] to improve the oral 
bioavailability of insulin. To perform in vivo absorption studies, 
chitosan was stained with FITC and insulin was labeled with 
Cy-3 (red), so to obtain Cy-3@insulin-loaded FITC@Ch/γ-
PGANPs, allowing their visualization. Wistar rats were sacri-
ficed 3 h after the oral administration of fluorescent NPs, and 
the intestinal epithelium was dissected, washed, fixed, and 
analyzed to the CLSM. Interestingly, a green fluorescent layer 
belonging to FITC@Ch/γ-PGANPs appeared on the surface of 
the gut microvilli. Instead, the red signal belonging to insulin 
was found on the lymphatic capillaries of the villi. These results 
suggested that Ch/γ-PGANPs released their cargo on the sur-
face of microvilli and insulin was then absorbed by the blood 
circulation, classifying Ch/γ-PGANPs as an efficient carrier for 
oral insulin delivery.[257]
A polyelectrolyte complex based on chitosan was also pre-
pared by He et  al.[259] to improve the oral drug delivery of 
insulin with a focus on the NPs’ size. A novel method, termed 
flash nanocomplexation, was employed to generate NPs. It con-
sisted of a device where the flow rates of four solutions (FITC@
Ch, sodium tripolyphosphate, insulin, and water) were adjusted 
to achieve an optimum size and obtain insulin-loaded FITC@
ChNPs. The resulting NPs had mean sizes of 45 and 115  nm 
and were characterized by narrow size distributions and effi-
cient encapsulation of insulin. Caco-2 cell monolayer was 
employed to assess the transport of both insulin-loaded FITC@
ChNPs and it was shown that 45 nm NPs could overcome the 
intestinal epithelium faster than the 115 nm NPs. Finally, con-
focal microscopy showed that 45 nm NPs were able to open TJs 
in a transient and reversible manner, determining a high con-
centration of insulin at the site of absorption.
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Thiolated chitosan is an efficient insulin vehicle and has 
enhanced mucoadhesive properties that increase the retention 
time of insulin in the gut.[260] Indeed, the free thiol group can 
enhance the covalent interaction with the glycoprotein mucin, 
found in the mucous layer of the ileum.[260] A recent study 
conducting by Sudhakar et  al.[261] determined the role of thi-
olated FITC@ChNPs as oral insulin delivery in mucoadhesion 
studies. The human intestinal Caco-2 cell line was used in cel-
lular uptake studies of NPs. Confocal images showed that NPs 
were efficiently uptaken by cells in a time-dependent manner. 
The uptake was attributed to the presence of thiol groups 
which, by inhibiting the protein tyrosine phosphatase, were 
able to open TJs.[262] Furthermore, in vivo testing was pursued 
to evaluate insulin biodistribution: fluorescent NPs were orally 
administered to Wistar rats and X-ray imaging showed that NPs 
appeared as a fluorescent layer on the top of the microvilli of 
the gut mucosa. This proved the ability of the drug delivery 
system to improve the bioavailability of insulin.
Liu et  al.[263] assessed the ability of FITC-labeled oleoyl-
carboxymethyl chitosan NPs (FITC@OCmChNPs) to act as 
oral protein carriers of a bacterial antigen. The biodistribution 
of NPs was investigated in vivo in carps and 48 h after oral 
administration, the carps were observed under the fluores-
cence microscopy. Results showed good tissue distribution of 
NPs since fluorescence was detected in some organs such as 
liver, spleen, heart, and gut. The high fluorescence in the gut 
indicated that FITC@OCmChNPs were efficient oral delivery 
systems, able to penetrate through the GI epithelium thanks to 
chitosan’s mucoadhesive properties.[263]
The behavior of FITC-labeled sulfate-modified-ChNPs 
loaded with bovine serum albumin (BSA), a model protein 
drug, was evaluated by CLSM in human Caco-2 intestinal epi-
thelial cell line.[264] The involvement of the physicochemical 
properties of NPs (e.g., difference in charge) in the internaliza-
tion of NPs by Caco-2 cells was investigated and it was found 
that the positively charged NPs were taken up more efficiently 
than the negative ones. Indeed, the intracellular fluorescent 
intensity of cells incubated with the positively charged BSA-
loaded FITC@ChNPs was assessed by flow cytometry and 
found to be greater than that given by treatment with nega-
tively charged NPs.[264]
Bagre et al.[265] focused their research on improving the oral 
bioavailability of low MW heparin by loading it in ChNPs. Hep-
arin is an anticoagulant drug characterized by poor permea-
tion through the GI epithelium and high instability in the GI 
tract.[266] To overcome the dissolution of chitosan at gastric pH, 
ChNPs were coated with sodium alginate (Sa) which tends to 
increase the stability of NPs in acidic pH.[267] Moreover, FITC 
was loaded for visualization of NPs in in vivo studies, so to 
obtain Sa-coated FITC@ChNPs. A gastric cannula was used 
to administer NPs to Sprague–Dawley rats which were sacri-
ficed 1 h after oral administration of NPs. The small intestine 
was extracted and analyzed by fluorescence microscopy. Strong 
green fluorescence was detected in the intestinal epithelium, 
implying a high uptake of the NPs. Further studies supported 
the hypothesis that Sa-coated ChNPs were suitable oral carriers 
for heparin since its bioavailability was significantly higher 
when loaded in Sa-coated ChNPs than when orally adminis-
tered plain in solution.[265]
In order to improve the mucoadhesion and stability of pro-
tein-loaded ChNPs, Soliman et  al.[268] modified the chitosan 
structure with hydro caffeic acid (HCA), known to increase the 
mucoadhesion of many polymers.[269] The ability of HCA-mod-
ified ChNPs to increase the oral absorption of a model protein 
drug was evaluated in ex vivo mucoadhesion investigations. To 
this end, chitosan was labeled with FITC so to obtain FITC@
Ch/HCANPs and allow quantification analysis. Rabbit small 
gut was removed, cut into small segments, and opened longi-
tudinally. Freeze-dried NPs were placed on top of the tissue and 
incubated for 10 min. The tissue was then immersed in 20 mL 
PBS and at different time intervals, 1 mL sample was removed 
and centrifuged. The content of FITC was quantified in the 
supernatant to determine the percentage of NPs that remained 
attached to the mucosa. It was found that HCA modification of 
chitosan enhanced the mucoadhesion of NPs sixfold compared 
to NPs generated from unmodified chitosan. Although more 
than 60% of NPs persisted on the mucosa, Ch/HCANPs could 
still enhance the mucoadhesion and hence the drug retention 
time and in turn, the drug bioavailability.[268]
7.2. Chitosan-Based NCs of Model Chemotherapeutic Agents
Nutraceuticals such as carotenoids have received significant 
attention owing to their biological and pharmaceutical prop-
erties including antioxidative and antitumorigenic activity.[270] 
However, their oral bioavailability is very poor since the GI 
epithelium prevents their absorption.[271] To improve their oral 
bioavailability, the development of colloidal nanocarrier delivery 
systems based on biodegradable and biocompatible materials 
such as chitosan is highly desirable.[272]
In a study performed by Dudhani and Kosaraju,[273] cat-
echin, a natural phenolic compound, was encapsulated in 
ChNPs whose mucoadhesive properties were evaluated with 
the help of FITC, in porcine intestinal tissues.[273,274] To carry 
out mucoadhesive studies, the entire tissue was immersed in 
a solution containing a known amount of FITC@NPs loaded 
with catechin or left unloaded. After that, the tissue was trans-
ferred in a lysozyme solution for cellular digestion. Following 
centrifugation, the supernatant was analyzed by spectrofluor-
ometry, and catechin-loaded fluorescent ChNPs showed higher 
bioadhesion (40%) than unloaded NPs (32%). This suggested 
a promising approach for ChNPs to improve the oral bioavail-
ability of catechin, probably due to enhanced hydrogen-bonding 
of the ChNPs.[273]
Epigallocatechin gallate (EG) is an active catechin, highly 
abundant in green tea, shown to have an important antitumoral 
role.[275] To increase its oral bioavailability, EG was encapsulated 
in FITC@Ch and caseinophosphopeptides (Cpp) nanocom-
plexes, according to a method described by Hu et  al.[276] The 
intestinal permeability of the fluorescent nanocomplexes was 
predicted in a Caco-2 cell monolayer by fluorescence micros-
copy.[277] The uptake of the EG-loaded nanocomplexes was 
confirmed by a strong fluorescent signal detected on the cell 
membrane and cytosol of cells treated with the nanocomplexes 
while no signal was detected in untreated cells. Moreover, 
experiments performed at increasing incubation times and 
concentrations of nanocomplexes showed that the uptake was 
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both time- and concentration-dependent. Finally, compared 
to the free form, EG encapsulated in Ch/Cpp nanocomplexes 
had enhanced permeation through the monolayer, suggesting a 
higher bioavailability.[277]
The oral absorption of Dox is limited mainly by the fact that 
it is recognized as a selective substrate of the P-glycoprotein 
(P-gp) efflux pump which is highly expressed on the GI epithe-
lium.[278] Therefore, several approaches have been explored by 
the literature to increase oral Dox absorption employing FITC@
ChNCs as its carrier. For instance, Yuan et al.[249] generated self-
aggregated micelles made of low MW chitosan modified with 
stearic acid (Sa) to transport the encapsulated Dox across the 
Caco-2 cell monolayer. FITC was conjugated to chitosan to 
obtain FITC@ChSa micelles which were added to the apical 
side of the monolayer at different temperatures (4, 25, and 
37 °C) and pH of the medium (5.9, 6.8, and 7.4). At given time 
intervals, solutions were collected from the basolateral chamber 
and their content of fluorescent micelles was determined by 
fluorescence spectrometry. Results showed that the permeation 
of micelles increased at temperature higher than 4 °C and pH 
lower than 7.4. This was attributed to the property of chitosan to 
become protonated at slightly acidic environments, establishing 
electrostatic interactions with the epithelium. The application 
of intracellular pathway inhibitors showed that micelles were 
able to cross the epithelium mainly by micropinocytosis. How-
ever, the measurement of the trans-epithelial electrical resist-
ance of the cellular membranes indicated that the paracellular 
route was also employed by micelles. The authors[249] concluded 
that by encapsulating Dox in ChSa micelles, Dox was able to 
overcome the P-gp.
Feng et  al.[279] generated pH-responsive NPs based on a 
polyelectrolyte complex: the water-soluble carboxymethyl chi-
tosan (CxCh) interacted with chitosan to increase stability of 
NPs in the GI tract. To enhance its oral bioavailability, Dox was 
encapsulated in this system which was conjugated with FITC 
to allow visualization of NPs in the GI tract, so as to form Dox-
loaded Ch/FITC@CxChNPs. Following oral administration 
to Sprague–Dawley rats of those NPs, their bioavailability and 
tissue distribution were examined in in vivo studies. Results 
showed poor absorption of Dox solution while its bioavailability 
was significantly higher when loaded in Ch/FITC@CxChNPs. 
Ex vivo studies were conducted to assess the intestinal mucoad-
hesion of Dox-loaded Ch/FITC@CxChNPs, 24 h after oral 
administration. The intestinal mucoadhesion was found to 
increase in the jejunum and ileum, suggesting that the pres-
ence of CxCh increased the absorption of Dox in these regions. 
Finally, ex vivo examination of organs was performed by con-
focal microscopy to assess tissue distribution of NPs. The pres-
ence of CxCh in the NPs allowed their detection in liver, spleen, 
and lung, while in the absence of CxCh, NPs were detected in 
the kidney for removal. These results suggested that Ch/FITC@
CxChNPs were able to extend the retention time of Dox in the 
blood, supporting the hypothesis that Ch/FITC@CxChNPs 
could be an efficient carrier for oral chemotherapy.[279,280]
In a study conducted by Khatik et  al.,[281] the surface of 
FITC@ChNPs was covered with the pH-responsive polymer 
Eudragit S 100 (Eds), to improve the oral bioavailability of cur-
cumin as a therapeutic agent for colon cancer. Indeed, Eds can 
effectively target the colon, dissolving at pH 7 hence releasing 
the drug at the target site while protecting it in the upper GI 
tract.[282] Eds-coated and uncoated FITC@ChNPs were orally 
administered to male Wistar rats and histopathological investi-
gations of stomach, small intestine, and colon were performed. 
Fluorescence was detected in the apical region of the stomach 
in the case of Eds-uncoated FITC@ChNPs, indicating adhesion 
in this part. Instead when FITC@ChNPs were coated with Eds 
no fluorescence was detected. In the small intestine, results 
were similar while stronger fluorescence was observed in the 
colon region when rats were treated with Eds-coated FITC@
ChNPs, suggesting improved uptake of those NPs in the colon 
owing to the presence of Eds.
7.3. Chitosan-Based NCs of Antibiotics Model
Taking advantage of the mucoadhesive properties of chitosan 
in the stomach, the corresponding NPs have been used in 
the delivery of antibiotics for the treatment of stomach infec-
tions, such as the one caused by Helicobacter pylori.[283] Indeed, 
most of the antibiotics, e.g., amoxicillin, used in this context 
are highly unstable and have a very short life (3–4 h) in the 
stomach environment,[284] but the encapsulation of antibiotics 
in ChNPs ensures their protection from the low pH and effi-
cient diffusion through the mucosa.[285] To this end, Arora[285] 
generated a polyelectrolyte complex composed of chitosan and 
alginate (Alg) and loaded with amoxicillin. Chitosan was labeled 
with FITC so to obtain optimized FITC@Ch/AlgNPs. FITC@
ChNPs formed by ionic gelation were taken as a control. Fluo-
rescent NPs were employed in in vitro mucoadhesion studies: 
after isolating the stomach from rat, FITC@Ch/AlgNPs were 
added and incubated for 20 min. The stomach was then washed 
and the number of NPs in the washing medium was analyzed. 
The percentage mucoadhesion of FITC@Ch/AlgNPs (≈75.9%) 
was lower than the control (≈88.5%), probably due to fewer 
amino groups being present on chitosan after interaction with 
the carboxylic groups of Alg, affording less interaction with 
the mucous layer.[286,287] However, the reduced mucoadhesion 
could be advantageous for NPs to permeate through the gastric 
mucosa and release their cargo at the site where Helicobacter 
pylori resides.[285] This hypothesis was confirmed by in vivo 
mucopenetration studies, carried out in Wistar rats. Animals 
were sacrificed at 1, 2, 4, and 6 h after oral administration of 
FITC@Ch/AlgNPs. The stomach was isolated and analyzed by 
fluorescence microscopy. NPs were localized deep in the gastric 
mucosa, especially in the antrum region, with the fluorescence 
intensity increasing with the incubation time. These results 
suggested the utility of FITC@Ch/AlgNPs in the context of 
antibiotic delivery to the stomach.
8. Conclusion
The labeling of ChNCs with FITC has gained impetus in the 
pharmaceutical and biomedical industry for its versatile appli-
cations. FITC@ChNCs are currently a common tool that 
extends the relevant properties of chitosan as a mucoadhesive 
polymer and acting as a permeation enhancer for the delivery 
of therapeutic agents. Indeed, owing to the mucoadhesive 
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characteristic, FITC@ChNCs can also be employed in the labe-
ling of cells for their in vivo tracking, allowing one to monitor 
their movement and migration. Moreover, the bioavailability 
of drugs such as insulin can be improved by FITC@ChNCs. 
Finally, investigations can be performed on both the physico-
chemical characteristics of NPs and the endocytic pathways 
undertaken by ChNCs according to the cell type. Altogether, 
these applications indicate the use of FITC@ChNCs as a 
further tool in the arsenal for the treatment and detection of 
tumors or other disorders.
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